



20 Annual 25 Report

Creating the future
in peptides

Financial Report

Consolidated financial statements

- 169** Consolidated income statement
- 170** Consolidated statement of comprehensive income
- 171** Consolidated statement of financial position
- 173** Consolidated statement of changes in equity
- 175** Consolidated statement of cash flows
- 177** Notes to the consolidated financial statements
- 217** Report of the statutory auditor

Consolidated income statement

1 January–31 December

kEUR	Note	2025	2024
Revenue	3	389,327	336,792
Other operating income	3	2,622	1,978
Total income		391,949	338,770
Cost of sales		-325,336	-299,422
Gross profit / (loss)		66,613	39,348
Marketing and sales expenses	3	-4,473	-3,866
Research expenses	3	-2,282	-1,095
General and administrative expenses	3	-51,169	-41,751
Total operating expenses		-57,924	-46,712
Operating result (EBIT)		8,689	-7,364
Financial income	3	1,843	6,802
Financial expenses	3	-30,589	-17,583
Total financial result		-28,746	-10,781
Result before income taxes		-20,057	-18,145
Income tax	5	-1,112	-1,419
Result for the year		-21,169	-19,564
Attributable to shareholders of PolyPeptide Group AG		-21,169	-19,564
Earnings per share in EUR, basic	7	-0.64	-0.59
Earnings per share in EUR, diluted	7	-0.64	-0.59

Consolidated statement of comprehensive income

1 January–31 December

kEUR	Note	2025	2024
Result for the year		-21,169	-19,564
Other comprehensive income to be reclassified to profit or loss in subsequent periods			
Exchange differences on translation of foreign operations, net of tax		-333	-523
Net other comprehensive income to be reclassified to profit or loss in subsequent periods		-333	-523
Other comprehensive income not to be reclassified to profit or loss in subsequent periods			
Remeasurement gain / (loss) on defined benefit plans	16	4,245	-6,490
Income tax effect	5	-927	1,392
Net other comprehensive income not to be reclassified to profit or loss in subsequent periods		3,318	-5,098
Other comprehensive result for the year, net of taxes		2,985	-5,621
Total comprehensive result for the year, net of taxes		-18,184	-25,185
Attributable to shareholders of PolyPeptide Group AG		-18,184	-25,185

Consolidated statement of financial position

As at 31 December

Assets, kEUR	Note	2025	2024
Non-current assets			
Intangible assets	8	13,908	15,018
Property, plant and equipment	9	437,249	364,541
Right-of-use assets	10	21,545	24,448
Deferred income tax assets	5	19,306	17,620
Other financial assets	24	7,512	5,164
Contract costs	3	1,563	1,563
Total non-current assets		501,083	428,354
Current assets			
Inventories	12	154,246	146,351
Trade receivables	13	60,864	82,499
Contract assets	3	3,441	3,761
Corporate income tax receivables		9,938	8,023
Other current assets	14	21,798	19,311
Cash and cash equivalents	15	74,589	68,277
Total current assets		324,876	328,222
Total assets		825,959	756,576

Consolidated statement of financial position (continued)

As at 31 December

Equity and liabilities, kEUR	Note	2025	2024
Equity attributable to equity holders of the parent company			
Share capital	6	302	302
Share premium		203,129	203,129
Translation reserve		20,976	21,309
Treasury shares	6	-6,466	-8,398
Other capital reserves		31	425
Retained earnings		122,626	140,477
Total equity		340,598	357,244
Non-current liabilities			
Deferred income tax liabilities	5	3,894	3,205
Pensions	16	29,849	32,133
Provisions	17	2,785	1,942
Interest-bearing loans and borrowings	19	109,034	39,420
Lease liabilities	10	15,979	18,982
Other financial liabilities	18	9,435	9,508
Contract liabilities	3	127,852	99,639
Total non-current liabilities		298,828	204,829
Current liabilities			
Interest-bearing loans and borrowings	19	544	30,642
Lease liabilities	10	5,008	5,073
Other financial liabilities	18	1,361	1,266
Corporate income tax payable		1,580	356
Trade payables	20	74,308	73,256
Contract liabilities	3	74,171	60,475
Other current liabilities	20	29,561	23,435
Total current liabilities		186,533	194,503
Total liabilities		485,361	399,332
Total equity and liabilities		825,959	756,576

Consolidated statement of changes in equity

1 January–31 December

Attributable to shareholders of PolyPeptide Group AG:

KEUR	Share capital	Share premium	Translation reserve	Treasury shares	Other capital reserves	Retained earnings	Total
Balance as at 1 January 2025	302	203,129	21,309	-8,398	425	140,477	357,244
Result for the year						-21,169	-21,169
Remeasurement gain / (loss) on defined benefit plans, net of tax						3,318	3,318
Currency exchange differences			-333				-333
Total comprehensive income	-	-	-333	-	-	-17,851	-18,184
Purchase of own shares				-484			-484
Share-based payment					2,022		2,022
Transfer of own shares				2,416	-2,416		-
Total transactions with owners	-	-	-	1,932	-394	-	1,538
Balance as at 31 December 2025	302	203,129	20,976	-6,466	31	122,626	340,598

Consolidated statement of changes in equity (continued)

1 January–31 December

Attributable to shareholders of PolyPeptide Group AG:

kEUR	Share capital	Share premium	Translation reserve	Treasury shares	Other capital reserves	Retained earnings	Total
Balance as at 1 January 2024	302	203,129	21,832	-10,394	1,217	165,139	381,225
Result for the year						-19,564	-19,564
Remeasurement gain / (loss) on defined benefit plans, net of tax						-5,098	-5,098
Currency exchange differences			-523				-523
Total comprehensive income	-	-	-523	-	-	-24,662	-25,185
Share-based payment					1,204		1,204
Transfer of own shares				1,996	-1,996		-
Total transactions with owners	-	-	-	1,996	-792	-	1,204
Balance as at 31 December 2024	302	203,129	21,309	-8,398	425	140,477	357,244

Consolidated statement of cash flows

1 January–31 December

kEUR	2025	2024
Cash flow from operating activities		
Result for the year	-21,169	-19,564
Adjustments to reconcile cash generated by operating activities		
Depreciation, amortization and impairment	38,066	32,714
Movement in provisions	1,031	195
Movement in pensions	-121	105
Share-based payment expense	2,022	1,204
Financial income	-1,843	-6,802
Financial expenses	30,589	17,583
Income tax expense / (income)	1,112	1,419
Changes in net working capital		
(Increase) / decrease in inventories	-11,100	-16,969
(Increase) / decrease in trade receivables	18,759	-5,009
(Increase) / decrease in contract assets	351	-1,669
(Increase) / decrease in other current assets	-7,777	-3,192
Increase / (decrease) in trade payables	5,636	11,372
Increase / (decrease) in contract liabilities	27,418	89,897
Increase / (decrease) in other current liabilities	5,589	-1,980
Cash generated from operations	88,563	99,304
Interest income received	1,823	586
Interest expenses paid	-9,112	-8,533
Income taxes paid	-3,764	-1,958
Net cash flows from operating activities	77,510	89,399
Cash flow from investing activities		
Acquisition of intangible assets	-1,152	-1,217
Acquisition of property, plant and equipment	-107,753	-85,751
Disposal of property, plant and equipment	587	2
Investments in other financial assets	-3,392	-2,489
Investments in contract costs	–	-1,563
Net cash flows from investing activities	-111,710	-91,018

Consolidated statement of cash flows (continued)

1 January–31 December

KEUR	2025	2024
Cash flow from financing activities		
Purchase of own shares	-484	–
Net proceeds from long-term borrowings from banks	50,000	–
Repayment of short-term borrowings from Draupnir Holding B.V.	-10,000	-10,000
Repayment of long-term borrowings from banks	–	-10,000
Repayment of lease liabilities	-4,951	-4,625
Repayment of other financial liabilities	-773	-698
Net cash flow from financing activities	33,792	-25,323
Net movement in cash and cash equivalents	-408	-26,942
Cash and cash equivalents at the beginning of the year	68,277	95,706
Net foreign currency exchange differences	6,720	-487
Cash and cash equivalents at the end of the year	74,589	68,277

Notes to the consolidated financial statements

General

PolyPeptide Group AG (the “Company”) is the holding company of a group of companies (the “Group”) engaged in the development, manufacturing and marketing of peptide-based compounds for use in the pharmaceutical and related research industries. The Group offers a full-service concept from early-stage custom development to contract manufacturing in both solid phase and solution phase technology.

The registered office of the Company is Neuhofstrasse 24, 6340 Baar, Switzerland.

As at 31 December 2025, the Company was a 55.47% subsidiary of Draupnir Holding B.V., a company registered in the Netherlands. Draupnir Holding B.V.’s ultimate controlling parent entity is Cryosphere Foundation, a foundation registered on Guernsey, of which Mr. Frederik Paulsen (Lausanne, Switzerland) is at present a named beneficiary pursuant to the charter of the foundation governed by the laws of Guernsey, although he has no vested interest in any portion of the foundation assets.

1 Summary of material accounting policy information

Basis of preparation

The consolidated financial statements of PolyPeptide Group AG and its subsidiaries have been prepared in accordance with the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB).

The financial year for the Group is 1 January–31 December 2025.

All amounts are stated in thousands of Euros (EUR), unless otherwise indicated.

Changes in accounting policies and presentation

The following amendments became mandatorily effective from 1 January 2025:

- Lack of Exchangeability (Amendments to IAS 21)

The adoption of the amendments to the IFRS Accounting Standards has not had any significant impact on the 2025 financial statements of the Group.

On 28 November 2025, the IASB issued Disclosures about Uncertainties in the Financial Statements – Illustrative examples, which amended multiple IFRS Accounting Standards to include illustrative examples demonstrating how companies can apply IFRS Accounting Standards when reporting the effects of uncertainties in their financial statements. The illustrative examples are accompanying materials to IFRS Accounting Standards and do not have an effective date. The IASB had issued a near-final staff draft of the illustrative examples in July 2025. The Group has considered these illustrative examples in its preparation of the consolidated financial statements and no additional disclosures or changes in presentation were considered necessary.

As a result, the accounting policies are consistent with prior years.

Principles of consolidation

The consolidated financial statements include the Company and its subsidiaries as at 31 December of each year. Subsidiaries are all entities over which the Group has control. The Group controls an entity where the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are consolidated from the date the Company obtains control until such time as control ceases.

The financial statements of the subsidiaries are prepared for the same reporting year as the parent company, using consistent accounting policies. Reference is made to Note 11 for information regarding the consolidated subsidiaries. All intra-group balances, income and expenses and unrealized gains and losses resulting from intra-group transactions are eliminated in full. A change in the ownership interest of a subsidiary, without loss of control, is accounted for as an equity transaction.

Translation of foreign currencies

The Group's consolidated financial statements are presented in Euros. The functional currency of the parent company is Swiss Franc (CHF). Each entity within the Group determines its own functional currency and items included in the financial statements of each entity are measured using that functional currency.

Translation of transactions and balances

Transactions in foreign currencies are initially recorded by the Group's entities at their functional currency spot rate at the date the transaction first qualifies for recognition. Monetary assets and liabilities denominated in foreign currencies are retranslated at the functional currency spot rate of exchange at the reporting date. Differences arising on settlement or translation of monetary items are recognized in the income statement.

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using exchange rates as at the dates of the initial transactions. When a gain or loss on a non-monetary item is recognized in other comprehensive income, any exchange component of that gain or loss is recognized in other comprehensive income. Conversely, when a gain or loss on a non-monetary item is recognized in profit or loss, any exchange component of that gain or loss is recognized in profit or loss.

Translation of subsidiaries

The functional currencies of the foreign operations are the Euro (EUR), US Dollar (USD), Indian Rupee (INR) and the Swedish Krona (SEK). As at the reporting date, the assets and liabilities of the subsidiaries with a functional currency other than the Euro are translated into the presentation currency of the Group (the Euro) at the rate of exchange ruling at the reporting date and their income statements are translated at the weighted average exchange rates for the year. The exchange differences arising on the translation are recorded in other comprehensive income. On disposal of a foreign entity, the component of other comprehensive income relating to that foreign operation is recognized in the income statement.

Any goodwill arising on the acquisition of a foreign operation and any fair value adjustments to the carrying amounts of assets and liabilities arising from the acquisition are treated as assets and liabilities of the foreign operation and translated at the closing rate.

Net investment in a foreign operation

One subsidiary has a monetary item that is receivable from another subsidiary. As of 1 October 2025, settlement of the inter-company loan (functional currencies EUR and USD) is neither planned nor likely to occur in the foreseeable future. As a result, the monetary item was reclassified and, in substance, became part of the parent company's net investment in the foreign operation. As of 1 October 2025, exchange differences arising from the translation of the loan into the functional currency of the parent company are therefore recognized in other comprehensive income and remain in equity, without subsequent reclassification to profit or loss unless the net investment is disposed of.

The parent company of the Group has a monetary item that is a receivable from one of its subsidiaries. As of 1 December 2024, settlement of the receivable is neither planned nor likely to occur in the foreseeable future. As a result, the monetary item became, in substance, a part of the parent company's net investment in the subsidiary. As of 1 December 2024, exchange differences arising from the translation of the receivable into the functional currency of the parent company are thus initially recognized in other comprehensive income in the consolidated financial statements and reclassified to profit or loss on disposal of the net investment.

Revenue recognition

Revenue is recognized to the extent it is probable that the economic benefits will flow to the Group and the revenue can be reliably measured, regardless of when the payment is being made. Revenue is measured at the fair value of the consideration received, excluding discounts, rebates, VAT and other taxes and duties. Revenue is recognized when a performance obligation is satisfied.

Performance obligations and timing of revenue recognition

The Group earns the majority of its revenues from the sale of goods. As a result, most of the Group's revenues are recognized at a point in time when control of the goods has transferred to the customer. All indicators of transfer of control according to IFRS 15 are normally in place when the Group delivers the goods to the customer. The level of judgement needed to determine the point in time at which a customer obtains control of the goods is thus limited.

When bill-and-hold arrangements are in place, the Group satisfies its performance obligation while still retaining physical possession of the goods until it is transferred to the customer at a point in time in the future. However, IFRS 15 clearly states four criteria that must be met for a customer to have obtained control of a product in a bill-and-hold arrangement. These criteria are reflected in the agreements with the customers, and the level of judgement needed for revenue recognition for bill-and-hold arrangements is thus also limited.

The Group has no sales contracts that include performance obligations relating to warranties or returns.

The Group also incurs a portion of its revenues in connection with pharmaceutical services like development and analytical services. In some cases, these contracts run longer than a year with revenue recognized typically on an over time basis. These service contracts are set up in a way to be distinct and the consideration related to the services is based upon standard hourly prices. For these services, the Group recognizes revenues based upon stage of completion which is estimated by comparing the number of hours actually spent on the project with the total number of hours expected to complete the project (i.e. an input-based method). This is considered a faithful depiction of the transfer of services as the contracts are initially priced on the basis of anticipated hours to complete the projects and therefore also represent the amount to which the Group would be entitled to based on its performance to date.

Determining the transaction price

With respect to the sale of goods, a transaction price is agreed in an order or order confirmation between the Group and its customer. Prices may also be included in the master service agreements, which are usually updated every year. However, the price in the order confirmation is controlling. There are no other variable components included in the transaction price such as payables to the customer, non-cash considerations, etc. All other special considerations such as volume discounts are calculated on a calendar-year basis and therefore do not result in any uncertainties about the amount of the transaction price at the end of the financial year. The transaction price for services is based upon a price list with standard prices (fair value) for different kind of services.

In determining the transaction price, the Group adjusts the promised amount of consideration for the effects of the time value of money if the timing of payments agreed to by the Group and the customer (either explicitly or implicitly) provides the Group with a significant benefit of financing the transfer of goods or services to the customer. The objective of this adjustment is to recognize revenue at an amount that reflects the price that a customer would have paid for the promised goods or services if the customer had paid cash for those goods or services when (or as) they transfer to the customer. When adjusting the promised amount of consideration for a significant financing component, the Group uses the discount rate that would be reflected in a separate financing transaction between the Group and its customer at contract inception.

If the Group expects, at contract inception, that the period between when the Group transfers a promised good or service to a customer and when the customer pays for that good or service will be one year or less, the Group applies a practical expedient and does not adjust the promised amount of consideration for the effects of a significant financing component.

Allocating amounts to performance obligations

As each performance obligation in a customer contract is generally priced against its fair value, only limited judgment is involved in the allocation of the total contract price to the individual performance obligations. This allocation will usually be determined by dividing the total contract price by the number of units ordered or hours spent.

Contract liabilities

If a customer pays consideration, or the Group has a right to an amount of consideration that is unconditional, before the Group transfers a good or service to the customer, the Group recognizes a contract liability when the payment is received, or the payment is due (whichever is earlier). The contract liability is derecognized and offset as revenue when the Group subsequently transfers the good or service to the customer.

Contract assets

A contract asset is defined as an entity's right to consideration in exchange for goods or services that the entity has transferred to a customer when that right is conditioned on something other than the passage of time (for example, the entity's future performance).

The Group recognizes a contract asset for unbilled work in progress related to the transfer of services where revenue is recognized 'over time'.

Contract assets are subject to impairment assessment. Please refer to the accounting policies on impairment of financial assets.

Contract costs

The Group capitalizes costs to fulfil a contract as 'Contract costs' if the costs incurred are not within the scope of another IFRS standard, and all of the following criteria are met:

- the costs relate directly to a contract or to an anticipated contract that the Group can specifically identify;
- the costs generate or enhance resources of the Group that will be used in satisfying (or in continuing to satisfy) performance obligations in the future; and
- the costs are expected to be recovered.

Capitalized contract costs are amortized in a manner that reflects the expected progress towards complete satisfaction of the related performance obligations. In most cases, this does not follow a straight-line basis over the contract terms.

Other income, costs and expenses

Other income, costs and expenses are allocated to the year to which they relate. Losses are accounted for in the year in which they arise.

Interest

For all financial instruments measured at amortized cost, interest income or expense is recorded using the effective interest rate. Interest income and expense is included in financial income and expense in the income statement.

Research expenses

Research expenses relating to Custom Projects are included in 'Cost of sales' in the income statement. Research expenses not relating to Custom Projects are presented on the separate financial line item 'Research expenses' in the income statement

Share-based payment

Share-based compensation is provided to members of the Board of Directors, the Executive Committee and certain other selected key employees (as applicable).

The programs are classified as equity arrangements where the fair value of the shares granted under the programs are recognized as an expense with a corresponding increase in equity. The fair value of the shares is measured at the market share price of PolyPeptide Group AG's shares, adjusted to take into account terms and conditions upon which the shares were granted. The total expense is recognized over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each period, the Company revises its estimates of the number of shares that are expected to vest based on the non-market vesting and service conditions. It recognizes the impact of the revision to original estimates, if any, in the income statement, with a corresponding adjustment to equity.

Taxes

Current income tax

Current income tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted by the reporting date. Corporate income tax is calculated on taxable profit according to the applicable tax rates in the various countries.

Current income tax relating to items recognized outside profit or loss is recognized outside profit or loss. Current income tax items are recognized in correlation to the underlying transaction either in profit or loss, through other comprehensive income or directly in equity.

Tax credits

Tax credits that can only be realized by a reduction of current or future corporate tax payments, rather than being directly settled in cash, are presented as part of the income tax charge for the year.

Deferred income tax

Deferred income tax is provided using the liability method on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.

Deferred income tax liabilities are recognized for all taxable temporary differences, except:

- When the deferred income tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and
- in respect to taxable temporary differences associated with investments in subsidiaries, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

Deferred income tax assets are recognized for all deductible temporary differences, the carry-forward of unused tax credits and any unused tax losses.

Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry-forward of unused tax credits and unused tax losses can be utilized, except:

- When the deferred income tax asset relating to the deductible temporary difference arises from initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither accounting profit nor taxable profit or loss; and

- in respect of deductible temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, deferred tax assets are only recognized to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized.

The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized. Unrecognized deferred income tax assets are reassessed at each reporting date and are recognized to the extent that it is probable that future taxable profit will allow the deferred tax asset to be recovered.

Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the assets are realized and the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred income tax relating to items recognized outside profit or loss is recognized outside profit or loss. Deferred tax items are recognized in correlation to the underlying transaction either in profit or loss, through other comprehensive income or directly in equity.

Deferred income tax assets and deferred income tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred income taxes relate to the same taxable entity and the same taxation authority.

VAT

Income, expenses and assets are recognized net of the amount of VAT, except:

- When the VAT incurred on a purchase of goods and services is not recoverable from the taxation authority, in which case the VAT is recognized as part of the cost of acquisition of the asset or as part of the expense item as applicable; and
- receivables and payables are stated with the amount of VAT included.

The net amount of VAT recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the statement of financial position.

Fair value measurements

The Group measures certain financial instruments at fair value. The fair values of financial instruments measured at amortized costs are disclosed in the financial statements. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability; or
- in the absence of a principal market, in the most advantageous market for the asset or liability.

The Group must be able to access the principal market or the most advantageous market at the measurement date.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data is available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs significant to the fair value measurement as a whole:

- Level 1 – Quoted (unadjusted) market prices in active markets for identical assets or liabilities.
- Level 2 – Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable.
- Level 3 – Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly unobservable.

For assets and liabilities that are recognized in the financial statements on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

Intangible assets

Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is the fair value as at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Internal development of software for internal use is recognized as intangible assets if the recognition criteria are met. Otherwise, the expenditure is reflected in the income statement in the year in which it is incurred. The useful lives of intangible assets are assessed to be either finite or indefinite.

Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible with a finite useful life are reviewed at least at each financial year end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization period or method, as appropriate, and treated as changes in accounting estimates. The amortization expense on intangible assets with finite useful lives is recognized in the income statement in the expense category consistent with the function of the intangible asset.

Gains or losses arising from the derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the income statement when the asset is derecognized.

Research and development costs

Research costs are expensed as incurred. Development expenditures on an individual project are recognized as an intangible asset when the Group can demonstrate:

- The technical feasibility of completing the intangible asset so that the asset will be available for use or sale
- Its intention to complete and its ability to use or sell the asset
- How the asset will generate future economic benefits
- The availability of resources to complete the asset
- The ability to measure reliably the expenditure during development
- The ability to use the intangible asset generated

Amortization of the asset begins when development is complete and the asset is available for use. It is amortized over the period of expected future benefit.

The Group's intangible assets consist of software that is amortized on a straight-line basis over five to ten years.

Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses. Such cost includes the costs of replacing part of the plant and equipment and borrowing costs for long-term construction projects if the recognition criteria are met. Likewise, when a major inspection is performed, its cost is recognized in the carrying amount of the plant and equipment as a replacement, if the recognition criteria are satisfied. All other repair and maintenance costs are recognized as dwelling costs in the income statement.

Depreciation is calculated on a straight-line basis over the estimated useful life of the asset, as stated hereunder.

• buildings (and leasehold improvements)	10 to 50 years
• machinery and equipment	3 to 20 years
• other	3 to 5 years

An item of property, plant and equipment is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognizing the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the income statement in the year the asset is derecognized.

The assets' residual values, useful lives and methods of depreciation are reviewed at each financial year end, and adjusted prospectively, if appropriate.

Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the respective

assets. All other borrowing costs are expensed in the period they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.

Impairment of non-financial assets

The Group assesses at each reporting date whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Group estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's fair value less costs to sell and its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. When the carrying amount of an asset or cash-generating unit exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

Financial assets

Initial recognition and measurement

Financial assets are classified at initial recognition and subsequently measured at amortized cost, fair value through other comprehensive income or fair value through profit or loss.

The classification of financial assets at initial recognition depends on the financial asset's contractual cash flow characteristics and the Group's business model for managing them. Except for trade receivables that do not contain a significant financing component or for which the Group has applied the practical expedient, the Group initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component or for which the Group has applied the practical expedient are measured at the transaction price determined under IFRS 15.

For a financial asset to be classified and measured at amortized cost or fair value through other comprehensive income, it needs to give rise to cash flows that are "solely payments of principal and interest" on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed at an instrument level.

The Group's business model for managing financial assets refers to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both.

Subsequent measurement

The subsequent measurement of financial assets depends on their classification as described below:

Financial assets at amortized cost (debt instruments)

This category is most relevant to the Group. The Group's financial assets at amortized cost mainly include trade receivables.

The Group measures financial assets at amortized cost if both of the following conditions are met:

- the financial asset is held within a business model with the objective to hold financial assets in order to collect contractual cash flows; and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Financial assets at amortized cost are subsequently measured using the effective interest method and are subject to impairment. Gains and losses are recognized in profit or loss when the asset is derecognized, modified, or impaired.

Factoring

In the reporting period beginning 1 January 2023, the Group decided to enter a non-recourse factoring agreement with a bank for a few selected customers. The arrangement is non-recourse between the Group and the bank where all risks and rewards of ownership of receivables are fully transferred to the bank, and where the Group does not provide any guarantee about the performance of the receivables. When the Group derecognizes the receivable from the customer and recognizes the consideration received from the bank, the difference between the carrying amount of the receivable and the consideration received from the bank is recognized as a financial expense in the income statement.

Impairment of financial assets

The Group recognizes an allowance for expected credit losses for all debt instruments not held at fair value through profit or loss. Expected credit losses are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from credit enhancements that are integral to the contractual terms.

Financial assets at amortized cost (debt instruments)

For trade receivables and contract assets, the Group applies a simplified approach in calculating expected credit losses. Therefore, the Group does not track changes in credit risk, but instead recognizes a loss allowance based on lifetime expected credit loss at each reporting date.

If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, the previously recognized impairment loss is reversed, to the extent that the carrying value of the asset does not exceed its amortized cost.

The Group considers a financial asset to be in default when internal or external information indicates that the Group is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Group. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.

Inventories

Inventories are valued at the lower of cost and net realizable value.

Costs incurred in bringing each product to its present location and condition are accounted for as follows:

Raw materials are recognized at standard cost at the time of purchase.

Finished goods and work-in-progress include costs of direct materials and labor and a proportion of manufacturing overhead based on normal operating capacity but excluding borrowing cost as the production does not require a substantial period of time.

Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

Other current assets

All other current assets are stated at the amounts at which they were acquired or incurred.

Cash and cash equivalents

Cash and cash equivalents in the statement of financial position and in the statement of cash flows comprise cash on hand and in banks and short-term deposits with an original maturity of three months or less.

Financial liabilities

Initial recognition and measurement

Financial liabilities are classified at initial recognition as financial liabilities at fair value through profit or loss, loans and borrowings and payables as appropriate.

All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs. The Group's financial liabilities include trade and other payables, loans and borrowings including bank overdrafts.

Subsequent measurement

After initial recognition, the financial liabilities are measured at amortized cost using the effective interest rate method. Gains and losses are recognized in the income statement when the liabilities are derecognized as well as through the effective interest rate amortization process. Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. The effective interest rate amortization is included in finance costs in the income statement.

Derecognition of financial assets and liabilities

Financial assets

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is derecognized when:

- the rights to receive cash flows from the asset have expired; or
- the Group has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a "pass-through" arrangement and either (a) the Group has transferred substantially all the risks and rewards of the asset, or (b) the Group has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Group has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, and has neither transferred nor retained substantially all the risks and rewards of the asset nor transferred control of the asset, the asset is recognized to the extent of the Group's continued involvement in the asset. If there is an

associated liability, the Group recognizes an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Group has retained.

Continued involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the net of the carrying amount and the maximum amount of the consideration that the Group could be required to repay.

Financial liabilities

A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expired. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and the recognition of a new liability, and the difference in the respective carrying amounts is recognized in the income statement.

Provisions

Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Group expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the income statement net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pre-tax discount rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognized as financial expenses in the income statement.

Pensions

The Group has insured contributory pension plans covering substantially all employees. Pension obligations are funded through annual premiums. The Group has defined benefit obligations to employees. The cost of providing benefits under the defined benefit plans is determined separately for each plan using the projected unit credit actuarial valuation method.

Remeasurements, comprising actuarial gains and losses and the return on plan assets (excluding net interest), are recognized immediately in the consolidated statement of financial position with a corresponding debit or credit to retained earnings through other comprehensive income in the period in which they occur. Re-measurements are not reclassified to profit or loss in subsequent periods.

Past service costs are recognized in profit or loss on the earlier of:

- the date of the plan amendment or curtailment; and
- the date that the Group recognizes restructuring-related costs

Net interest is calculated by applying the discount rate to the net defined benefit liability or asset.

The net defined benefit liability is the aggregate of the present value of the defined benefit obligation and the fair value of plan assets out of which the obligations are to be settled. Plan assets are assets that are held by a long-term employee benefit fund or qualifying insurance policies.

Plan assets are not available to the creditors of the Group, nor can they be paid directly to the Group. Fair value is based on market price information and in the case of quoted securities it is the published bid price.

Leases

All leases are accounted for by recognizing a right-of-use asset and a lease liability, except for:

- Leases of low value assets; and
- Leases with a term of 12 months or less.

Lease liabilities are measured at the present value of the contractual payments due to the lessor over the lease term, with the discount rate determined by reference to the rate inherent in the lease unless (as is typically the case) this is not readily determinable, in which case the Group's incremental borrowing rate on commencement of the lease is used. Variable lease payments are only included in the measurement of the lease liability if they depend on an index or rate. In such cases, the initial measurement of the lease liability assumes that the variable element will remain unchanged throughout the lease term. Other variable lease payments are expensed in the period to which they relate.

On initial recognition, the carrying value of the lease liability also includes:

- amounts expected to be payable under any residual value guarantee;

- the exercise price of any purchase option granted in favor of the Group if it is reasonably certain to assess that option;
- any penalties payable for terminating the lease, if the term of the lease has been estimated on the basis of a termination option being exercised.

Right-of-use assets are initially measured at the amount of the lease liability, reduced for any lease incentives received, and increased for:

- lease payments made at or before commencement of the lease;
- initial direct costs incurred; and
- the amount of any provision recognized where the Group is contractually required to dismantle, remove or restore the leased assets.

Subsequent to initial measurement, lease liabilities are increased as a result of interest charged at a constant rate on the balance outstanding and are reduced for lease payments made. If the lease transfers ownership of the underlying asset by the end of the lease term or if the cost of the right-of-use asset reflects that a purchase option will be exercised, the right-of-use asset is depreciated from the commencement date to the end of the useful life of the underlying asset. Otherwise, the right-of-use asset is depreciated from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term.

When the Group revises its estimate of the term of any lease (because, for example, it re-assesses the probability of a lessee extension or termination option being exercised), it adjusts the carrying amount of the lease liability to reflect the revised net present value of future lease payments. The carrying amount of lease liabilities is similarly revised when the variable element of future lease payments dependent on a rate or an index is revised. In both cases, an equivalent adjustment is made to the carrying amount of the right-of-use asset, with the revised carrying amount being depreciated over the remaining (revised) lease term.

Other liabilities

All other liabilities are stated at the amounts at which they were acquired or incurred.

Cash flow statement

The cash flow statement is prepared according to the indirect method. Cash and cash equivalents comprise cash on hand and in banks and short-term deposits with an original maturity of three months or less. Interest and income tax cash flows are included in the cash flow from operating activities.

Future changes in accounting policies

The following standards, amendments to standards, and interpretations have been issued by the IASB and are mandatorily effective for reporting periods beginning 1 January 2026 or later. The Group has not early adopted any of these and does not believe these standards, amendments to standards, and interpretations will have a material impact on the recognition and measurements of financial items in the consolidated financial statements once adopted:

- Amendments to the Classification and Measurement of Financial Instruments (Amendments to IFRS 9 and IFRS 7)
These amendments provide additional clarification and disclosure requirements relating to the derecognition of financial liabilities and classification of financial assets. The Group does not expect these changes to have a material impact on its financial instruments.
- Contracts Referencing Nature-dependent Electricity (Amendments to IFRS 9 and IFRS 7)
The amendments clarify accounting treatment for nature-dependent electricity contracts. The Group is assessing potential implications for its electricity procurement contracts; no significant impact is anticipated.

- **IFRS 18 *Presentation and Disclosure in Financial Statements***

IFRS 18 replaces IAS 1 and introduces new requirements aimed at improving comparability, transparency and the usefulness of financial information. The new standard is effective for annual reporting periods beginning on or after 1 January 2027, with retrospective application required.

Although IFRS 18 will not impact the Group's net profit or the recognition and measurement of financial statement items, the Group expects presentation-related changes in several areas:

Statement of profit or loss – Income and expenses will be presented within new mandatory categories (operating, investing and financing). Certain foreign exchange effects currently shown in finance income/expense may be reclassified and presented above operating profit.

Aggregation and disaggregation – IFRS 18 strengthens the principles for providing meaningful, structured information. While the content of disclosures is expected to remain broadly consistent, the grouping of information may change.

New disclosures – The standard introduces expanded requirements, including: – management-defined performance measures (MPMs), – a breakdown of the nature of expenses for line items presented by function in the operating category, and – a reconciliation in the first year of application between IAS 1 and IFRS 18 presentation.

Statement of cash flows – The starting point will change to operating profit, and interest received/paid will be reclassified to investing/financing cash flows, respectively.

The Group is currently assessing the detailed impact of IFRS 18. Based on preliminary analysis, no material impact on equity, total comprehensive income or cash flows is expected.

- **IFRS 19 *Subsidiaries without Public Accountability: Disclosures***

Effective from 1 January 2027, this standard provides reduced disclosure requirements for eligible subsidiaries.

The Group is assessing the applicability of IFRS 19 to certain subsidiaries. However, IFRS 19 will have no impact on the consolidated financial statements.

Significant accounting judgments and estimates

The preparation of the Group's consolidated financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.

Estimates and assumptions

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below. The Group based its assumptions and estimates on parameters available when the consolidated financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising beyond the control of the Group. Such changes are reflected in the assumptions when they occur.

Impairment of non-financial assets

The Group assesses whether there are any indicators of impairment for all non-financial assets at each reporting date and tests for impairment when there are indicators that the carrying amounts may not be recovered. When value in use calculations is undertaken, management must estimate the expected future cash flows from the asset or cash-generating unit and choose a suitable discount rate to calculate the present value of those cash flows. Even though 2024 and 2025 were characterized by a volatile macroeconomic environment, the Group has not identified any indicators of impairment. No impairment losses of non-current assets have thus been recognized in 2025 (2024: No impairment losses).

Pension and other employment benefits

The cost of defined benefit pension plans is determined using actuarial calculations. The actuarial calculations include assumptions about discount rates, future salary increases, and life expectancy. Due to the complexity of the valuation, the underlying assumptions and its long-term nature, a defined benefit obligation is highly sensitive to changes in these assumptions (see Note 16).

Deferred income tax assets

Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management's judgement is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and level of future taxable profits together with future tax planning strategies (see Note 5).

2 Segment information

PolyPeptide generates revenue that is presented in Note 3. Effective as of the start of the current reporting period, for a more concise discussion of business drivers, the Company now has two primary business areas “Commercial revenue” and “Development revenue”.

This revised presentation reflects the distinction between revenue from ongoing commercial supply activities and revenue from early-stage development collaborations.

The chief operating decision maker (i.e., the Executive Committee) reviews revenue generated within each business area but does not review results at this disaggregated level. As a result, the two business areas are not considered two separate operating segments since only revenue information for each area is reviewed by the chief operating decision maker. The Group continues to have one operating segment in accordance with IFRS 8 – *Operating segments*.

The segment disclosures are thus provided in accordance with the requirements applicable for entities that have a single reportable segment.

Revenue from major customers (10% or more of total revenue)

In 2025, revenues of approximately kEUR 56,890 and kEUR 47,980, respectively, were derived from two customers. In 2024, revenues of approximately kEUR 43,900 and kEUR 41,200, respectively, were derived from two customers.

Geographical areas

Shown below are the carrying amounts of non-current assets other than deferred income tax assets and other financial assets, broken down by location of the assets. Related additions to intangible assets and property, plant and equipment (PP&E) during the year and revenues generated from the location of the assets are shown as well.

2025 kEUR	USA	Europe & India	Total
Revenue	98,083	291,244	389,327
Additions to intangible assets and PP&E	4,888	105,090	109,978
Non-current assets, carrying amount	78,553	394,149	472,702

2024 kEUR	USA	Europe & India	Total
Revenue	94,419	242,373	336,792
Additions to intangible assets and PP&E	3,698	84,141	87,839
Non-current assets, carrying amount	96,692	307,315	404,007

3 Revenue and expenses

PolyPeptide generates revenue that can be divided into the two business areas described below:

Revenue by business area

kEUR	2025	2024
Development revenue	153,431	118,148
Commercial revenue	235,896	218,644
Total revenue	389,327	336,792

Development revenue (formerly Custom Projects) business area specializes in the manufacturing of custom research-grade peptides, in milligram, gram or pilot scale quantities, at predefined purity levels for use in pre-clinical and clinical development as well as for regulatory and scientific studies. Development also provides cGMP manufacturing services during the later phases of development. Revenue is allocated to Development for sales of products in the pre-clinical through clinical stage development (i.e., prior to commercial launch) as generally set out in master service agreements and/or the accompanying work / purchase orders.

Commercial revenue (formerly Contract Manufacturing/Generics and Cosmetics) business area manufactures peptides for commercial stage peptide therapeutics, at scale, in commercial batches and in accordance with cGMP requirements. The Group's Commercial services also include consultation for continuous improvement and process stabilization / optimization to support scale-up, process changes to support cost of goods sold enhancement, lifecycle management and extension as well as regulatory support. Revenue is allocated to Commercial where production is related to the commercial supply, as generally set out in master supply agreements and/or the accompanying work / purchase orders. In addition, Commercial also includes manufacturing of peptide-based generics for the human and veterinary market. The business area also includes revenue generated from the sale of peptides used in cosmetics.

Revenue by geographical area

Revenue is attributed to the individual geographical area based on the invoice address of the respective customer.

kEUR	2025	2024
Americas	99,623	89,727
Europe	258,503	208,828
Asia Pacific	30,359	35,612
Others	842	2,625
Total revenue	389,327	336,792

Revenue from contracts with customers

2025 kEUR	API	Related services	Total
Timing of transfer of goods and services			
Point in time	360,118		360,118
Over time		29,209	29,209
Total revenue	360,118	29,209	389,327
2024			
kEUR	API	Related services	Total
Timing of transfer of goods and services			
Point in time	307,752		307,752
Over time		29,040	29,040
Total revenue	307,752	29,040	336,792

Revenues from Active Pharmaceutical Ingredients (API) fully relate to the sale of goods and revenues from related services relate to the rendering of services. All revenues from contracts with customers classify as business-to-business.

Contract assets and contract liabilities

Contract assets

kEUR	2025	2024
Balance as at 1 January	3,761	2,103
Transfer in the period from contract assets to trade receivables	-4,563	-1,986
Transfer of services to customers during the year where the right to payment as at 31 December is conditioned on something other than the passage of time	4,212	3,655
Currency exchange differences	31	-11
Balance as at 31 December	3,441	3,761

Contract liabilities

kEUR	2025	2024
Balance as at 1 January	160,114	66,129
Amounts included in contract liabilities that were recognized as revenue during the period	-62,514	-20,506
Cash received in advance of performance and not recognized as revenue during the period	92,101	110,403
Interest expense from financing components	6,871	4,905
Currency exchange differences	5,451	-817
Balance as at 31 December	202,023	160,114

Contract costs

kEUR	2025	2024
Balance as at 1 January	1,563	-
Asset recognized from costs incurred to fulfil a contract during the period	-	1,563
Balance as at 31 December	1,563	1,563

In 2025, the Group incurred costs of nil in relation to setup activities required in order to satisfy future performance obligations (2024: 1,563). The costs in 2024 (i) directly relate to two contracts with customers, (ii) have generated resources that will be used in satisfying the performance obligations in the contracts, and (iii) are expected to be recovered. Since the nature of the costs incurred is not within the scope of another IFRS standard, the costs incurred have been capitalized as an asset from costs to fulfil a contract in accordance with IFRS 15 – Revenue from Contracts with Customers.

The asset will be amortized in a way that reflects the expected progress towards complete satisfaction of the performance obligations. It is not expected that this will be on a straight-line basis over the terms of the contracts.

Other operating income

kEUR	2025	2024
Research refund	1,218	1,457
Invoiced freight and insurance	270	307
Investment grants	78	75
Sale of intellectual property	1,439	-
Other	-383	139
Total other operating income	2,622	1,978

The research refund relates to a deduction on tax paid due to qualified research in chemistry. The investment grants relate to improving air emission handling, etc. Sale of intellectual property mainly reflects proceeds from the disposal of internally generated know-how that had not previously been capitalized.

Marketing and sales expenses

kEUR	2025	2024
Salaries and employee benefits	-3,029	-2,683
Marketing and promotion costs	-668	-657
Other	-776	-526
Total marketing and sales expenses	-4,473	-3,866

Research expenses

kEUR	2025	2024
Salaries and employee benefits	-1,901	-814
Other	-381	-281
Total research expenses	-2,282	-1,095

General and administrative expenses

kEUR	2025	2024
Salaries and employee benefits	-20,301	-16,538
Other staff expenses	-3,016	-2,341
Depreciation, amortization and impairment loss	-1,390	-2,725
Professional services	-10,257	-7,045
Insurance cost	-2,732	-2,409
IT services	-3,975	-2,519
License fees and royalties	-3,951	-3,607
Other	-5,547	-4,567
Total general and administrative expenses	-51,169	-41,751

Financial income

kEUR	2025	2024
Interest income due from third parties	1,823	586
Other financial income	20	34
Foreign currency exchange gains	-	6,182
Total financial income	1,843	6,802

Financial expenses

kEUR	2025	2024
Interest expenses due to third parties	-10,330	-8,943
Foreign currency exchange losses	-12,273	-
Financing expenses on financing components	-6,871	-4,905
Other financial expenses	-1,115	-3,735
Total financial expenses	-30,589	-17,583

Staff costs

kEUR	2025		2024	
	Indirect	Direct	Indirect	Direct
Salaries and wages	-20,557	-88,230	-15,817	-79,927
Social charges	-4,106	-18,690	-3,341	-16,809
Pension costs	-573	-6,817	-877	-5,805
Total staff cost	-25,236	-113,737	-20,035	-102,541

An amount of kEUR 113,737 (2024: kEUR 102,541) relating to salaries and employee benefits has been included in cost of sales.

The average number of FTEs of the principal departments is as follows:

Average number of employees

	2025	2024
Production	786	722
Marketing and sales	20	18
Research and development	167	168
General and administration	114	103
Quality control	178	161
Quality assurance	130	119
Total	1,395	1,291

Depreciation and amortization included in the income statement

Included in Cost of sales:

kEUR	2025	2024
Depreciation	-33,182	-27,460
Amortization	-2,197	-2,413
Impairment	-1,297	-116
Total	-36,676	-29,989

Included in General and administrative expenses:

kEUR	2025	2024
Depreciation	-1,304	-1,271
Amortization	-85	-85
Impairment	-1	-1,369
Total	-1,390	-2,725

4 Share-based payment

The following equity-settled share-based payment arrangements are recognized in the consolidated financial statements:

Board of Directors

Members of the Board of Directors receive at least half of their fixed fees in shares, with the option to elect to be paid up to 100% of their fixed fee in shares. For Board members electing to receive more than 50% of their fixed fee in shares, the shares exceeding the 50% portion are granted at a discount of 20% to market price. The proportion between shares (in excess of 50%) and cash is selected by each Board member upon election at the general meeting and is fixed until the next general meeting. The Board of Directors is compensated on a pro-rata basis for the period of service, even in the case of early termination or removal.

In 2025, the fair value at grant date amounted to kEUR 795 (2024: kEUR 785), reflecting a measurement based on a total number of shares of 51,895 (2024: 25,796) considering a 20% discount for any portion of the fee exceeding 50% of the total board compensation paid in shares. All shares will be fully vested at the general meeting in April 2026. In 2025, a total amount of kEUR 798 (2024: kEUR 802) was recognized as "General and administrative expenses" in the income statement according to the principles of graded vesting in IFRS 2.

Executive Committee and selected key employees

The Board of Directors has adopted a Long-Term Incentive Plan ("LTIP") for Executive Committee members and selected key employees of the Group. Under this share-based incentive program, eligible participants are awarded the contingent right to receive a certain number of shares in the future ("PSU(s)") in the Company, subject to, inter alia, continued employment and achievement of market as well as non-market performance targets. The actual number of PSUs that will eventually vest and be settled in shares depends on revenue, EBITDA, and Total Shareholder Return ("TSR") performance of the Group over a three-year performance period.

- In H1 2024, 30 employees of the Group, including members of the Executive Committee, were granted PSUs in the Company. The total fair value at grant date amounted to kEUR 3,408. The fair value at grant date for the PSUs conditioned on revenue and EBITDA performance (i.e., non-market vesting conditions) amounted to kEUR 2,629, reflecting a measurement based on 81,640 number of PSUs potentially vesting and the share price of PolyPeptide Group AG as of the grant date of EUR 32, adjusted for a value cap of 500% at vesting. The impact of the value cap has been determined based on a Monte-Carlo simulation. The fair value at grant date for the PSUs conditioned on TSR performance amounted to kEUR 779, reflecting a measurement based on 17,499 number of PSUs and a fair value per PSU of EUR 45. The fair value per PSU is determined based on a Monte-Carlo simulation that also incorporates a value cap of 500% at vesting.
- In H2 2024, three employees of the Group were granted PSUs in the Company. The total fair value at grant date amounted to kEUR 38. The fair value at grant date for the PSUs conditioned on revenue and EBITDA performance (i.e., non-market vesting conditions) amounted to kEUR 30, reflecting a measurement based on 1,056 number of PSUs potentially vesting and the share price of PolyPeptide Group AG as of the grant date of EUR 28, adjusted for a value cap of 500% at vesting. The impact of the value cap has been determined based on a Monte-Carlo simulation. The fair value at grant date for the PSUs conditioned on TSR performance amounted to kEUR 8, reflecting a measurement based on 226 number of PSUs and a fair value per PSU of EUR 38. The fair value per PSU is determined based on a Monte-Carlo simulation that also incorporates a value cap of 500% at vesting.

- In H1 2025, 41 employees of the Group, including members of the Executive Committee, were granted PSUs in the Company. The total fair value at grant date amounted to kEUR 3,557. The fair value at grant date for the PSUs conditioned on revenue and EBITDA performance (i.e., non-market vesting conditions) amounted to kEUR 3,203, reflecting a measurement based on 154,364 number of PSUs potentially vesting and the share price of PolyPeptide Group AG as of the grant date of EUR 21, adjusted for a value cap of 500% at vesting. The impact of the value cap has been determined based on a Monte-Carlo simulation. The fair value at grant date for the PSUs conditioned on TSR performance amounted to kEUR 354, reflecting a measurement based on 33,076 number of PSUs and a fair value per PSU of EUR 11. The fair value per PSU is determined based on a Monte-Carlo simulation that also incorporates a value cap of 500% at vesting.
- In H2 2025, one employee of the Group joined the Long-Term Incentive Plan and was granted PSUs in the Company. The total fair value at grant date amounted to kEUR 101. The fair value at grant date for the PSUs conditioned on revenue and EBITDA performance (i.e., non-market vesting conditions) amounted to kEUR 85, reflecting a measurement based on 3,602 PSUs potentially vesting and the share price of PolyPeptide Group AG as of the grant date of EUR 24, adjusted for a value cap of 500% at vesting. The impact of the value cap has been determined based on a Monte-Carlo simulation. The fair value at grant date for the PSUs conditioned on TSR performance amounted to kEUR 16, reflecting a measurement based on 772 PSUs and a fair value per PSU of EUR 20. The fair value per PSU is determined based on a Monte-Carlo simulation that also incorporates a value cap of 500% at vesting. During H2 2025, 1,235 PSUs granted to two participants were forfeited due to termination of employment prior to vesting. In accordance with IFRS 2, the related share-based payment expense recognized in prior periods was reversed, and no further expense is recognized in respect of these forfeited awards.

The participants are compensated for missed dividend payments during the vesting period if the PSUs vest. As a result, expected dividends during the vesting period have not impacted the fair value measurements of the grant.

An expense of kEUR 1,223 (2024: kEUR 512) has been recognized in 2025 as "General and administrative expenses" in the income statement relating to these grants.

Chief Executive Officer

The CEO of the Group, Juan Jose Gonzalez, is participating in the share-based incentive program described above. In addition to these, he was also granted PSUs on 6 September 2023 ("2023 CEO Grant"). The vesting of the PSUs for the 2023 CEO Grant depends on RONOA and EPS performance of the Group over a three-year performance period.

In accordance with IFRS 2, the maximum number of shares potentially vesting was used for the determination of the fair value of the grant. As a result, the fair value at grant date amounted to kEUR 1,135, reflecting a measurement based on 51,060 number of PSUs and the share price of PolyPeptide Group AG as of the grant date of EUR 23. The vesting period ends 10 trading days after the shareholders approve the 2025 audited consolidated financial statements.

The participant is compensated for missed dividend payments during the vesting period if the PSUs vest. As a result, expected dividends during the vesting period have not impacted the fair value measurement of the grant.

In 2025, no expense has been recognized in the income statement since it is expected that no PSUs from the 2023 CEO Grant will eventually vest. In H1 2024, an amount of kEUR 146 was recognized as "General and administrative expenses" in the income statement. This amount has been reversed in H2 2024.

5 Taxation

Taxation includes local and foreign taxation. Major components of the tax expense were:

kEUR	2025	2024
Consolidated income statement		
Current income tax charge	-3,640	-1,139
Deferred income tax charge	2,528	-280
Total income tax charge	-1,112	-1,419
Consolidated statement of comprehensive income		
Income tax directly charged to comprehensive income	-927	1,392
Total income tax charge (credit)	-927	1,392

Amounts recorded in the consolidated statement of comprehensive income related to deferred income taxes on actuarial gains and losses on defined benefit plans as a result of IAS 19.

A reconciliation of the income tax charge applicable to profit from operating activities before income tax at the Swiss statutory income tax rate to income tax expense at the Company's effective income tax rate for the years ended 31 December was as follows:

kEUR	2025	2024
Result before income taxes	-20,057	-18,145
At Swiss statutory income tax rate of 11.8 %	2,368	2,142
Different income tax rates of other countries	450	2,904
Non-deductible expenses and non-taxable income	844	-737
Non-capitalized tax losses	-9,077	-7,986
R&D tax credits	3,733	3,640
Effect of change in tax rates	80	-239
Adjustments in respect of current income tax of previous year	490	-1,143
At an effective income tax rate of -5.5% (2024: -7.8%)	-1,112	-1,419

The effective tax rate for 2025 is -5.5% (2024: -7.8%). The Group has recorded a limited tax expense, despite the loss before tax. This low tax expense is mainly due to non-capitalized tax assets, partly offset by R&D tax credits incurred in the US group entities in 2025.

Non-capitalized tax losses are also related to further build-up of tax losses in Polypeptide Group AG, due to the current year loss making position. A deferred tax asset has not been recognized for the tax losses due to uncertainty on whether the tax losses will be utilized before expiry (tax losses in Switzerland expire after seven years).

Income from R&D tax credits is related to US R&D tax credits. This income is subsequently reversed through the impairment of the US deferred tax assets.

The deferred tax assets include an amount of kEUR 2,682 (2024: kEUR 2,757) relating to US R&D tax credits that have been claimed, but for which uncertainty exists on whether these will be sustained by the US tax authorities.

kEUR	2025	2024
Differences in carrying amount and fiscal valuation of assets and liabilities	7,169	5,872
Capitalized tax losses carried forward	12,137	11,748
Total deferred income tax assets	19,306	17,620

The deferred tax assets for losses carried forward relate to tax losses of PolyPeptide Laboratories Holding (PPL) AB (Sweden) and PolyPeptide Laboratories France S.A.S. (France) and PolyPeptide A/S (Denmark). The tax losses are expected to be offset against future taxable profits which are expected to be realized within the foreseeable future.

The valuation of deferred tax assets for losses carried forward are based on management approved medium-term budgets. Tax losses are expected to be utilized within five years.

The net deferred tax asset compose of temporary differences, mainly related to intangible assets, inventory, pension liabilities, deferred tax deduction of book expenses as well as unutilized R&D tax credits in PolyPeptide Laboratories Inc. (USA), including accounting for uncertainty on whether this can be sustained by US tax authorities.

The Group has unrecognized tax loss carry forwards available for losses incurred in various countries approximating mEUR 36.6 (2024: mEUR 1,155), of which mEUR 19.1 (2024: mEUR 10.2) has no expiration date and mEUR 17.5 will expire between 2028 and 2032. No deferred income tax asset has been recognized due to uncertainty with respect to available taxable profits in the future for these tax jurisdictions and the limitations imposed in tax legislation in order to utilize the tax losses.

The significant decrease in unrecognized deferred tax losses is caused by PolyPeptide Group AG's reassessment of the valuation approach for its investment in PolyPeptide Laboratories Holding (PPL) AB in accordance with the Swiss Code of Obligations. Management determined that the quoted market price of PolyPeptide Group AG no longer provided the most appropriate basis for estimating the recoverable amount of the investment. The recoverable amount is now determined with reference to the consolidated IFRS net-equity value of PolyPeptide Laboratories Holding (PPL) AB and its subsidiaries, which is considered a more reliable indicator under the current circumstances. The change in the valuation approach and the associated tax treatment has been confirmed by the respective tax authority. Consequently, the tax losses incurred because of the impairment of the investment no longer exist, but have been replaced by a temporary difference related to the tax value of the investment.

No deferred tax asset has been recognized for the temporary difference of mEUR 1,894, as PolyPeptide Group AG does not yet meet the probability threshold for having sufficiently reliable evidence that future taxable profits will be available to utilize the temporary difference.

The effect of this accumulated tax deduction and corresponding valuation allowance on the deferred tax asset has been reported through equity. As no net deferred tax asset is recognized for the tax loss generated by this tax deduction, there is no net tax effect reported in equity.

Deferred income tax liabilities as at 31 December relate to the following:

kEUR	2025	2024
Differences in carrying amount and fiscal valuation of assets and liabilities	3,894	3,205
Total deferred income tax liabilities	3,894	3,205

Differences in the carrying amount and tax values of assets and liabilities mainly relate to differences in valuation of Land & Buildings and Machinery & Equipment.

The deferred income tax charge relates to the following:

kEUR	2025	2024
Movement in deferred tax assets	1,686	931
Movement in deferred tax liability	-689	439
Translation differences	604	-258
Total deferred income tax charge	1,601	1,112

kEUR	2025	2024
Deferred tax charge in income statement	2,528	-280
Deferred tax (credit) / charge in statement of comprehensive income	-927	1,392
Total deferred income tax charge	1,601	1,112

Translation differences mainly relate to Swedish Krona and United States Dollar.

6 Shareholders' equity

Share capital

There have been no changes to the share capital of the parent company of the Group, PolyPeptide Group AG, during 2025. As a result, the share capital of PolyPeptide Group AG comprised 33,125,001 registered shares with a nominal value of CHF 0.01 each as at 31 December 2025.

All shares are fully paid-up.

Treasury shares

	Number of shares	Average purchase/ transfer price (EUR)	% of number of shares in share capital
Own shares as at 1 January 2025	128,505		0.4%
Purchase	25,455	19	0.1%
Transfer	-35,524	68	-0.1%
Own shares as at 31 December 2025	118,436		0.4%
Own shares as at 1 January 2024	155,494		0.5%
Purchase	–	–	–
Transfer	-26,989	74	-0.1%
Own shares as at 31 December 2024	128,505		0.4%

Cash distribution

No cash distribution was made in 2025 (2024: no cash distribution).

7 Earnings per share

KEUR	2025	2024
Result for the year attributable to shareholders of PolyPeptide Group AG	-21,169	-19,564
Weighted average number of shares ('000)	33,125	33,125
Weighted average number of own shares ('000)	130	145
Weighted average number of outstanding shares ('000)	32,995	32,980
Dilution effect of share-based payment ('000)	34	20
Weighted average number of diluted shares ('000)	33,029	33,000
Earnings per share (EPS), basic	-0.64	-0.59
Earnings per share (EPS), diluted	-0.64	-0.59

Basic earnings per share has been calculated by dividing the result for the year attributable to the owners of PolyPeptide Group AG by the weighted average number of shares outstanding during the year. Treasury shares are not considered as outstanding shares.

Diluted earnings per share is calculated by dividing the result for the year attributable to the owners of PolyPeptide Group AG by the weighted average number of shares outstanding adjusted for all potentially dilutive shares. Dilutive shares arise from the share-based payment described in Note 4.

8 Intangible assets

The Group's intangible assets only consist of software.

kEUR	Software
Acquisition value	
Balance as at 1 January 2025	30,980
Additions	1,172
Disposals	-269
Currency exchange differences	-69
Balance as at 31 December 2025	31,814
Accumulated amortization and impairment losses	
Balance as at 1 January 2025	-15,962
Amortization	-2,282
Disposals	269
Currency exchange differences	69
Balance as at 31 December 2025	-17,906
Carrying value as at 31 December 2025	13,908

kEUR	Software
Acquisition value	
Balance as at 1 January 2024	29,884
Additions	1,062
Disposals	-
Currency exchange differences	34
Balance as at 31 December 2024	30,980
Accumulated amortization and impairment losses	
Balance as at 1 January 2024	-13,430
Amortization	-2,498
Disposals	-
Currency exchange differences	-34
Balance as at 31 December 2024	-15,962
Carrying value as at 31 December 2024	15,018

As at 31 December 2025, the carrying amount of software includes an amount of EUR 7.8 million (2024: EUR 7.1 million) that is still under construction. This software will be taken into use in subsequent periods and hence no amortization has been recognized for this software yet.

The Group assesses whether there are any indicators of impairment for all non-financial assets at each reporting date. If any indicators of impairment have been identified, the Group calculates the amount of impairment as the difference between the recoverable amount of the asset and its carrying value and recognizes the impairment loss in the income statement. The Group has not identified any indicators of impairment during the year.

9 Property, plant and equipment

kEUR	Land & Buildings	Machinery & Equipment	Assets under construction	Total
Acquisition value				
Balance as at 1 January 2025	147,365	319,814	88,425	555,604
Additions	231	878	107,697	108,806
Disposals	-99	-4,503	-	-4,602
Transfers	3,865	51,923	-55,788	-
Currency exchange differences	-9,037	-5,025	1,048	-13,014
Balance as at 31 December 2025	142,325	363,087	141,382	646,794
Accumulated depreciation and impairment losses				
Balance as at 1 January 2025	-59,144	-131,919	-	-191,063
Depreciation	-6,748	-22,879	-	-29,627
Impairment losses	-	-1,298	-	-1,298
Disposals	89	3,926	-	4,015
Currency exchange differences	3,814	4,614	-	8,428
Balance as at 31 December 2025	-61,989	-147,556	-	-209,545
Carrying value as at 31 December 2025	80,336	215,531	141,382	437,249

kEUR	Land & Buildings	Machinery & Equipment	Assets under construction	Total
Acquisition value				
Balance as at 1 January 2024	129,943	243,991	91,168	465,102
Additions	30	1,444	85,303	86,777
Disposals	-	-1,165	-1,485	-2,650
Transfers	13,088	73,541	-86,565	64
Currency exchange differences	4,304	2,003	4	6,311
Balance as at 31 December 2024	147,365	319,814	88,425	555,604
Accumulated depreciation and impairment losses				
Balance as at 1 January 2024	-50,877	-113,643	-	-164,520
Depreciation	-6,642	-17,588	-	-24,230
Impairment losses	-	-	-1,485	-1,485
Disposals	-	1,163	1,485	2,648
Transfers	-	-15	-	-15
Currency exchange differences	-1,625	-1,836	-	-3,461
Balance as at 31 December 2024	-59,144	-131,919	-	-191,063
Carrying value as at 31 December 2024	88,221	187,895	88,425	364,541

In 2024, the Group decided to exercise a purchase option of a right-of-use asset. As a result, the asset was reclassified from right-of-use assets to property, plant and equipment. This is reflected in the table above by the net transfer of kEUR 64 (acquisition value) and kEUR 15 (accumulated depreciation), respectively.

The Group assesses whether there are any indicators of impairment for all non-financial assets at each reporting date. If any indicators of impairment have been identified, the Group calculates the amount of impairment as the difference between the recoverable amount of the asset and its carrying value and recognizes the impairment loss in the income statement.

During 2025, the Group determined that certain machinery within the production facility was no longer in use and has no expected future economic benefit. As a result, the carrying amount of these assets was reviewed and written down to their recoverable amount. An impairment loss of kEUR 1,298 was recognized in the year.

During 2024, the Group decided to discontinue the development of certain assets under construction. As a result, an impairment loss of kEUR 1,486 was recognized, reflecting a recoverable amount of nil after the impairment.

The amount of borrowing costs capitalized during the year was kEUR 2,199 (2024: nil).

As at 31 December 2025, the carrying amount of Land & Buildings includes an amount of approximately kEUR 6,000 (2024: kEUR 6,300) for which the legal ownership is no longer with the Group due to the transaction with Monedula AB, as further disclosed in Note 18.

10 Leases

Set out below are the carrying amounts of right-of-use assets recognized in the statement of financial position and the movements during the year:

kEUR	Buildings	Cars	Other equipment	Total
Cost of right-of-use assets				
Balance as at 1 January 2025	25,397	5,034	8,421	38,852
Additions	2,010	1,246	30	3,286
Remeasurements	74	-75	160	159
Disposals	-	-691	-479	-1,170
Transfer to tangible assets (see Note 9)	-	-	-	-
Currency exchange differences	-2,145	17	-149	-2,277
Balance as at 31 December 2025	25,336	5,531	7,983	38,850
Accumulated depreciation				
Balance as at 1 January 2025	-9,031	-2,198	-3,175	-14,404
Depreciation	-2,617	-1,279	-963	-4,859
Disposals	-	669	469	1,138
Transfer to tangible assets (see Note 9)	-	-	-	-
Currency exchange differences	781	-7	46	820
Balance as at 31 December 2025	-10,867	-2,815	-3,623	-17,305
Carrying value as at 31 December 2025	14,469	2,716	4,360	21,545

kEUR	Buildings	Cars	Other equipment	Total
Cost of right-of-use assets				
Balance as at 1 January 2024	21,600	4,235	8,357	34,192
Additions	1,822	1,478	466	3,766
Remeasurements	1,000	-1	13	1,012
Disposals	-156	-667	-409	-1,232
Transfer to tangible assets (see Note 9)	-	-	-64	-64
Currency exchange differences	1,131	-11	58	1,178
Balance as at 31 December 2024	25,397	5,034	8,421	38,852
Accumulated depreciation				
Balance as at 1 January 2024	-6,520	-1,673	-2,476	-10,669
Depreciation	-2,294	-1,158	-1,049	-4,501
Disposals	142	629	346	1,117
Transfer to tangible assets (see Note 9)	-	-	15	15
Currency exchange differences	-359	4	-11	-366
Balance as at 31 December 2024	-9,031	-2,198	-3,175	-14,404
Carrying value as at 31 December 2024	16,366	2,836	5,246	24,448

Set out below are the carrying amounts of the lease liabilities recognized in the statement of financial position and the movements during the year:

kEUR	Buildings	Cars	Other equipment	Total
Lease liabilities				
Balance as at 1 January 2025	16,914	2,887	4,254	24,055
Additions	2,010	1,181	30	3,221
Interest expenses	441	78	83	602
Remeasurements	73	2	83	158
Lease payments	-2,852	-1,379	-1,322	-5,553
Currency exchange differences	-1,424	13	-85	-1,496
Balance as at 31 December 2025	15,162	2,782	3,043	20,987
Lease liabilities				
Balance as at 1 January 2024	15,542	2,593	5,187	23,322
Additions	1,674	1,460	402	3,536
Interest expenses	470	78	127	675
Remeasurements	985	-15	13	983
Lease payments	-2,560	-1,222	-1,518	-5,300
Currency exchange differences	803	-7	43	839
Carrying value as at 31 December 2024	16,914	2,887	4,254	24,055

The maturity of the total undiscounted lease liability as at 31 December is disclosed in Note 23.

The following amounts are recognized in the income statement:

kEUR	2025	2024
Depreciation expense of right-of-use assets	4,859	4,501
Interest expense on lease liabilities	602	675
Variable lease payments not included in the lease liabilities	–	49
Short-term leases (included in G&A expenses)	590	1,153
Leases of low-value assets (included in G&A expenses)	3,264	367
Total amount recognized in the income statement	9,315	6,745

The Group had total cash outflows for leases of kEUR 9,407 in 2025 (2024: kEUR 6,869).

The total lease liability of the Group mainly relates to leases of buildings in Torrance, California, USA. The remaining lease liability largely consists of machinery and company cars in various Group companies, primarily having fixed monthly lease payments.

11 Investments in subsidiaries

The consolidated financial statements include the financial statements of the Company and the subsidiaries listed below. Details of investments in subsidiaries as at 31 December are as follows:

Name	Location	Percentage of ownership	
		2025	2024
Polypeptide Laboratories Holding (PPL) AB	Limhamn, Sweden	100%	100%
Polypeptide Laboratories (Sweden) AB	Limhamn, Sweden	100%	100%
PolyPeptide SA	Braine-l'Alleud, Belgium	100%	100%
PolyPeptide Laboratories France S.A.S.	Strasbourg, France	100%	100%
PolyPeptide Laboratories Inc.	Torrance, CA, USA	100%	100%
PolyPeptide Laboratories San Diego, LLC ¹	San Diego, CA, USA	100%	100%
PolyPeptide Laboratories Pvt. Ltd.	Ambarnath (East), India	100%	100%
PolyPeptide Laboratories A/S ²	Hillerød, Denmark	100%	100%

¹ PolyPeptide Laboratories San Diego, LLC is a wholly owned subsidiary of PolyPeptide Laboratories Inc.

² PolyPeptide Laboratories A/S is a dormant company.

Percentage of voting shares is equal to percentage of ownership.

12 Inventories

kEUR	2025	2024
Raw materials and supplies	73,426	80,143
Work in progress	69,174	45,215
Finished goods	11,646	20,993
Balance as at 31 December	154,246	146,351

Raw materials that are expired or that are no longer used in production, and finished goods for which no future sales are expected, are fully written down at the balance sheet date. Finished goods that are expected to be sold after retesting are written down for the expected loss during this retesting. The estimated loss is approximately 10% of the original weight of the batch.

Costs of inventories recognized in cost of sales in the income statement during the financial year amounted to kEUR 141,615 (2024: kEUR 132,771).

Provisions for obsolete stock amounted to kEUR 55,030 as at 31 December 2025 (2024: kEUR 51,282). Inventory write downs recognized in cost of sales in the income statement during the financial year 2025 amounts to kEUR 23,069, mainly due to inventory write-downs in Belgium and USA (2024: kEUR 13,636, mainly due to inventory write-downs in Belgium).

13 Trade receivables

kEUR	2025	2024
Trade receivables	60,864	82,499
Balance as at 31 December	60,864	82,499

Trade receivables are non-interest bearing and are generally on 30–90 day terms.

The Group has entered into a non-recourse factoring agreement with a bank for a few selected customers. The arrangement is non-recourse between the Group and the bank where all risks and rewards of ownership of receivables are fully transferred to the bank, and where the Group does not provide any guarantee about the receivables' performance. As a result, PolyPeptide has no continuing involvement in the transferred receivables.

When the receivable is derecognized, the difference between the carrying amount of the receivable and the consideration received from the bank is recognized as a financial expense in the income statement.

In 2025, consideration received from the bank as part of the non-recourse factoring agreement amounted to kEUR 95,212 (2024: kEUR 50,551) which resulted in a related financial expense of kEUR 579 (2024: kEUR 388).

The aging analysis of trade receivables is as follows:

kEUR	Total	< 30 days	30-60 days	60-90 days	90-120 days	> 120 days
31 December 2025	60,864	55,574	3,575	1,308	10	397
31 December 2024	82,499	70,004	11,183	786	66	460

The Group applies the IFRS 9 simplified approach to measuring expected credit losses using a lifetime expected credit loss provision for trade receivables and contract assets. To measure expected credit losses on a collective basis, trade receivables and contract assets are grouped based on similar credit risk and aging. The contract assets have similar risk characteristics to the trade receivables for similar types of contracts.

A significant part of the outstanding accounts receivable balance relates to large reputable pharmaceutical companies with no known history of write-offs. The expected credit loss for these large pharmaceutical companies is estimated at

nil. For smaller outstanding debtors, the expected loss rates are based on the Group's historical credit losses experienced over a three-year period prior to the end of the reporting period. These historical loss rates are then adjusted for current and forward-looking information on macroeconomic factors affecting the Group's customers.

Movements in the bad debt allowance for trade receivables are as follows:

kEUR	2025	2024
Balance as at 1 January	622	279
Increase in bad debt allowance	131	572
Receivable written-off during the year as uncollectible	-387	-197
Unused amounts reversed	-	-37
Currency exchange difference	-39	5
Balance as at 31 December	327	622

14 Other current assets

kEUR	2025	2024
Prepaid expenses	5,761	5,994
VAT receivable	12,717	13,173
Withholding tax receivable	1,074	-
Other	2,246	144
Balance as at 31 December	21,798	19,311

"Other" mainly comprises advance payments to suppliers.

15 Cash and cash equivalents

For the purpose of the Consolidated Statement of Cash Flows, cash and cash equivalents comprise the following as at 31 December of each year:

kEUR	2025	2024
Cash and cash equivalents	74,589	68,277
Balance as at 31 December	74,589	68,277

Changes in liabilities arising from financing activities for the years were as follows:

kEUR	Non-current interest- bearing loans and borrowings	Current interest- bearing loans and borrowings	Non-current other financial liabilities	Lease liabilities	Current other financial liabilities
Balance as at 1 January 2025	39,420	30,642	9,508	24,055	1,266
Cash flows	46,442	-11,568	–	-5,553	-1,266
Non-cash flows					
New lease liabilities	–	–	–	3,221	–
Remeasurements	–	–	170	158	–
Accrued interest	4,095	1,322	588	602	–
Transfer from current to non-current	20,000	-20,000	-1,361	–	1,361
Currency exchange differences	-923	148	530	-1,496	–
Balance as at 31 December 2025	109,034	544	9,435	20,987	1,361

kEUR	Non-current interest bearing loans and borrowings	Current interest- bearing loans and borrowings	Non-current other financial liabilities	Lease liabilities	Current other financial liabilities
Balance as at 1 January 2024	49,087	41,253	9,893	23,322	1,227
Cash flows	-13,154	-13,551	–	-5,300	-1,227
Non-cash flows					
New lease liabilities	–	–	–	3,536	–
Remeasurements	–	–	714	983	–
Accrued interest	3,487	2,940	604	675	–
Transfer from non-current to current	–	–	-1,266	–	1,266
Currency exchange differences	–	–	-437	839	–
Balance as at 31 December 2024	39,420	30,642	9,508	24,055	1,266

16 Pensions

The Group participates in local pension plans in the countries in which it operates. The pension plans are either structured as defined contribution plans or defined benefit plans:

- Defined contribution plans, where the Group is only obliged to pay a pension premium to a fund or insurance company on behalf of the employee. Contributions to defined contribution pension schemes are recognized as incurred in the consolidated income statement.
- Defined benefit plans, where the Group is obliged to provide pension benefits related to services rendered based on final salary levels. The obligation arising from the defined benefit plans is recognized as a net defined benefit obligation in the statement of financial position. This plan is used in Sweden, France, Belgium, India and Switzerland.

The majority of the total net defined benefit obligation recognized in the consolidated financial statements relates to the entities in Sweden and Belgium. For each of the defined benefit plans, no trust is established, and the full liability is recorded in the statement of financial position with compulsory insurance coverage.

The Swedish net defined benefit obligation is calculated by a third-party institution, the Pension Registration Institute (PRI). PRI also administrates the pension payments to employees, which are subsequently charged to the company.

The Belgian fund is outsourced to an insurance company called AXA Insurance. All funds requested to cover the year are called by and paid to the insurance company. The net defined benefit obligation is calculated by a third-party institution, Willis Towers Watson.

The movement in the net defined benefit obligation is shown on the following pages.

kEUR	Present value of obligation	Fair value of plan assets	Net defined benefit obligation
Balance as at 1 January 2025	55,366	-23,233	32,133
Amounts recognized in the income statement			
Current service cost	3,038	–	3,038
Past service cost	–	–	–
Interest expense (+) / income (-)	1,773	-757	1,016
Total amount recognized in the income statement	4,811	-757	4,054
Remeasurements recognized in other comprehensive income			
Return on plan assets, excluding amounts included in interest (income)	–	155	155
Actuarial gain (-) or loss (+) from changes in demographic assumptions	-319	–	-319
Actuarial gain (-) or loss (+) from changes in financial assumptions	-1,191	–	-1,191
Actuarial gain (-) or loss (+) from changes in experience	-2,890	–	-2,890
Change in asset ceiling, excluding amounts included in interest expense	–	–	–
Total amount recognized in other comprehensive income	-4,400	155	-4,245
Exchange differences	1,047	55	1,102
Contributions:			
By employer	-323	-2,300	-2,623
By plan participants	318	-890	-572
Payments from plan:			
Benefit payments	67	-67	–
Settlements	–	–	–
Balance as at 31 December 2025	56,886	-27,037	29,849

There was no impact of minimum funding requirements or asset ceiling on the net defined benefit obligation in 2025.

kEUR	Present value of obligation	Fair value of plan assets	Net defined benefit obligation
Balance as at 1 January 2024	44,123	-19,012	25,111
Amounts recognized in the income statement			
Current service cost	2,510	–	2,510
Past service cost	–	–	–
Interest expense (+) / income (-)	1,748	-806	942
Total amount recognized in the income statement	4,258	-806	3,452
Remeasurements recognized in other comprehensive income			
Return on plan assets, excluding amounts included in interest (income)	–	-6	-6
Actuarial gain (-) or loss (+) from changes in financial assumptions	5,687	–	5,687
Actuarial gain (-) or loss (+) from changes in experience	809	–	809
Change in asset ceiling, excluding amounts included in interest expense	–	–	–
Total amount recognized in other comprehensive income	6,496	-6	6,490
Exchange differences	-518	9	-509
Contributions:			
By employer	-277	-2,134	-2,411
By plan participants	230	-230	–
Payments from plan:			
Benefit payments	1,054	-1,054	–
Settlements	–	–	–
Balance as at 31 December 2024	55,366	-23,233	32,133

There was no impact of minimum funding requirements or asset ceiling on the net defined benefit obligation in 2024.

Pension expenses reflected in the income statement

kEUR	2025	2024
Current service costs	3,038	2,510
Net interest costs	1,016	942
Defined benefit costs	4,054	3,452
Defined contribution costs	3,336	3,230
Total pension expenses	7,390	6,682

Weighted average principal assumptions used in determining the present value of the defined benefit obligation

kEUR	2025	2024
Discount rate (%)	3.60%	3.15%
Future salary increases (%)	3.08%	3.34%
Remaining life expectancy at the time of retirement (years):		
Male	22.4	22.1
Female	25.3	25.1

Sensitivity to changes in assumptions

Changes in the assumptions will impact the defined benefit pension obligation as at 31 December as follows:

kEUR	2025		2024	
	Increase	Decrease	Increase	Decrease
Discount rate (+/- 0.5%)	-3,679	4,447	-4,043	4,652
Future salary increases (+/- 0.5%)	2,395	-2,104	2,318	-2,066
Life expectancy (+/- 1 year)	915	-936	796	-1,149

Expected contributions to the plan for next annual reporting period

The Group expects to pay kEUR 3,889 in contributions to defined benefit plans in 2026 (2025: kEUR 3,605).

Weighted average duration

The weighted average duration of the defined benefit obligation is 14.51 years (2024: 15.5 years).

17 Provisions

kEUR	2025	2024
Provision for restoration costs	2,360	1,746
Provision for litigation	–	147
Other provisions	425	49
Balance as at 31 December	2,785	1,942

The provision for restoration costs relates to the requirement to return leased properties of the Torrance facility into the conditions required by the terms and conditions of the lease agreements and depollution activities for other sites.

In 2024, the provision for litigation relates to labor law claims from former employees.

Movement of the provision for the years was as follows:

kEUR	2025	2024
Balance as at 1 January	1,942	1,649
Utilization	-147	-27
Additions through profit or loss	1,178	248
Reversals through profit or loss	–	-26
Currency exchange differences	-188	98
Balance as at 31 December	2,785	1,942

18 Other financial liabilities

kEUR	2025	2024
Financial liability to Monedula AB	10,796	10,774
Total other financial liabilities as at 31 December	10,796	10,774
Non-current other financial liabilities	9,435	9,508
Current other financial liabilities	1,361	1,266
Total other financial liabilities as at 31 December	10,796	10,774

Financial liability to Monedula AB

In December 2019, PolyPeptide Laboratories (Sweden) AB sold all its shares in PolyPeptide Fastighets AB to related party Draupnir Holding B.V. PolyPeptide Fastighets AB was subsequently renamed into Monedula AB.

Monedula AB is the owner of the premises that are leased by PolyPeptide Laboratories (Sweden) AB. At transaction date, PolyPeptide Laboratories (Sweden) AB and Monedula AB extended the existing lease agreement to 31 December 2035.

Although the legal ownership of the premises was transferred to the buyer, management concluded that the transfer of the premises did not satisfy the requirements of IFRS 15 to be accounted for as a sale of the asset. Therefore, the carrying value of the premises as at the transaction date remained in the consolidated statement of financial position of the Group.

The consideration received for the premises in the amount of SEK 124.8 million (kEUR 11,997) was recognized as a financial liability and accounted for in accordance with IFRS 9 as prescribed in IFRS 16.103(a).

The financial liability is currently measured at amortized cost using an effective interest rate of 5.57% (2024: 5.57%). The financial liability matures on 31 December 2035 and will be settled with future lease terms payable to Monedula AB. The total carrying value of the liability as at 31 December 2025 amounts to SEK 116.8 million (kEUR 10,796), of which SEK 14.7 million (kEUR 1,361) is presented as a current financial liability. The total carrying value of the liability as at 31 December 2024 amounted to SEK 123.5 million (kEUR 10,774), of which SEK 14.5 million (kEUR 1,266) was presented as a current financial liability.

The lease payments change each year based on changes in a consumer price index. When the adjustment to the lease payments takes effect, the financial liability is remeasured to reflect the new net present value of the future lease payments.

19 Interest-bearing loans and borrowings

As at the reporting date, the Company had in place a revolving credit facility agreement provided by UBS Switzerland AG, Zürcher Kantonalbank and Danske Bank (the "RCF"). During 2025, the Company amended and restated the RCF, increasing the capital commitments from EUR 111 million to EUR 151 million and extending the term to March 2028.

The RCF agreement includes a financial covenant. For each period of twelve months ending on 30 June or 31 December in any year, the Group must comply with a predetermined financial ratio that is based on debt and earnings.

One of the lenders participating in the RCF has issued a bank guarantee in the amount of EUR 10 million in favor of one of the Group's customers in relation to amounts received for (i) manufacturing capacity reservations and (ii) raw material prepayments. The amount of the bank guarantee has reduced the available drawings under the RCF accordingly.

The interest rate on the RCF amounted to EURIBOR plus an average margin of 2.95% in 2025 per annum. In H1 2025, the margin was 2.60% per annum and in H2 2025, the margin was 3.15% per annum (H1 2024: 3.40% per annum and H2 2024: 2.45%). As at 31 December 2025, an amount of kEUR 90,000 was drawn from the RCF (31 December 2024: kEUR 40,000).

As at the reporting date, the Company also had in place a subordinated credit facility with its main shareholder, Draupnir Holding B.V., in the amount of EUR 20 million, which was fully drawn as at 31 December 2025 (31 December 2024: kEUR 30,000) (the "Draupnir Facility"). During 2025, the Company amended and restated the Draupnir Facility extending the term to May 2027. The interest rate on the Draupnir Facility amounts to three-month EURIBOR plus a margin between 3.25% and 3.95% (2024: 3.25% and 4.20%) per annum on the amounts drawn.

As at 31 December 2025, an amount of kEUR 1,200 was granted by ING Bank (31 December 2024: kEUR 1,200), of which nil was drawn (31 December 2024: nil). In 2025 and 2024, the interest rate on the ING Bank credit facility amounted to 1-month EURIBOR plus a margin of 1.2% on the amounts drawn, and a facility fee of 0.30% on the total facility amount.

20 Trade payables and other current liabilities

kEUR	2025	2024
Trade payables	74,308	73,256
Total trade payables	74,308	73,256
Taxes and social securities	12,056	7,694
Accrued expenses	16,168	14,848
Other	1,337	893
Total other current liabilities	29,561	23,435

Trade payables and other current liabilities are non-interest-bearing.

21 Contingent liabilities and guarantees

Limited partnership investment

In November 2021, the Group entered into a limited partnership agreement with a commitment to invest a maximum amount of kUSD 30,000. Two capital calls were made during 2025, where the Group invested a total of kUSD 3,600 in addition to investments made in prior years. The investments are recognized as "Other financial assets" in the consolidated statement of financial position and measured at fair value through profit or loss.

As at 31 December 2025, the Group thus has remaining a contingent liability of kUSD 17,400 (kEUR 14,809) (2024: kUSD 21,000 and kEUR 20,215).

If the general partner of the limited partnership makes an additional capital call, the Group would be obliged to pay the amount within ten business days.

Guarantee pension fund

All members of the PRI Pensionsgaranti, the issuer of the defined benefit plan in Sweden, are subject to a mutual liability. This liability would only be invoked in the event that PRI Pensionsgaranti has consumed all its assets. The mutual liability of the Group is limited to a maximum of 2% of the Group's individual pension liability with PRI Pensionsgaranti. As such, the Group has a contingent liability of kEUR 325 as at 31 December 2025 (2024: kEUR 288), for which it has issued a guarantee to PRI Pensionsgaranti.

Belgian labor authorities– settlement concluded

The Belgian labor authorities (Service Public Fédéral – Emploi, Travail et Concertation Sociale) conducted a partial audit of the PolyPeptide site in Braine-l'Alleud in July 2023. In 2024, the Group disclosed that the audit report identified several potential findings and that the outcome was uncertain. At that time, in accordance with IAS 37.25–26, no provision was recognized because a reliable estimate of the potential outflow could not be made due to the wide range of possible outcomes.

During 2025, settlement agreements with the affected employees were signed. The related court case initiated by the Belgian labor authorities was formally closed in February 2026, following PolyPeptide's acceptance of a settlement proposal amounting to kEUR 19. All legal and administrative procedures have been completed and the matter is now considered closed.

22 Related parties

The following transactions have been entered into with related parties:

2025 kEUR	Income from related parties	Purchases from related parties	Amounts due from related parties	Amounts due to related parties
Thalamus AB	–	-155	–	-605
Ferring Group	36,618	–	586	-327
Monedula AB	34	-1,362	35	-10,796
Nordic Pharma Inc	4	–	–	–
SVAR Life Science AB	62	–	–	–
Nordic Pharma Ltd.	–	–	–	–
Limhamn Kajan 37 AB	–	-17	–	-882

2024 kEUR	Income from related parties	Purchases from related parties	Amounts due from related parties	Amounts due to related parties
Thalamus AB	–	-149	–	-694
Ferring Group	43,939	-466	5,354	–
Monedula AB	114	-1,302	–	-10,774
Nordic Pharma Inc (formerly Amring Pharmaceuticals Inc)	3	–	–	–
SVAR Life Science AB	193	-3	–	–
Nordic Pharma Ltd.	–	-2	–	–
Limhamn Kajan 37 AB	–	-48	–	-586

In addition to the information shown in the table above, PolyPeptide Group AG secured in 2023 a short-term credit facility from its main shareholder, Draupnir Holding B.V. As a result, interest expenses at the amount of kEUR 1,322 have been incurred during the year (2024: kEUR 2,941). As at 31 December 2025, an amount of kEUR 20,000 was drawn from the credit facility (2024: kEUR 30,000) and is accordingly recognized in the consolidated statement of financial position as a non-current liability (see Note 19).

All disclosed related parties are either related through the Esperante Investments S.à r.l. ownership structure or through managerial control. Esperante Investments S.à r.l. is a higher parent company of the majority shareholder Draupnir Holding B.V.

Purchases from and amounts due to Thalamus AB relate to rental of premises.

Income from and amounts due from the Ferring Group relate to sale of goods.

Purchases from Monedula AB relate to the lease of premises. Income from Monedula relate to property management fees and recharged improvements to the premises. Amounts due to Monedula AB relate to the financial liability recognized for the lease of premises as disclosed in Note 18.

Income from SVAR Life Science AB relates to sale of goods.

Purchases from and amounts due to Limhamn Kajan 37 AB relate to rental of premises.

During 2025, no provisions for doubtful debt and no write-offs on receivables from related parties were recognized (2024: nil). No guarantees were given or received in 2025 for any outstanding related party balances (2024: nil).

Transactions with key management personnel

Compensation of key management personnel of the Group:

kEUR	2025	2024
Salaries and short-term benefits	3,808	3,557
Post-employment benefits	287	286
Share-based payment expense	1,654	1,082
Total transactions with key management	5,749	4,925

Reference is made to Note 4 for further details on the share-based payment expense.

Key management personnel are considered all members of the Executive Committee and the Board of Directors.

23 Financial risk management objectives and policies

The Group's principal financial instruments comprise trade receivables, cash and cash equivalents, trade payables, lease liabilities, other financial liabilities and interest-bearing loans and borrowings. The market risk, credit risk and liquidity risk relating to the Group's financial instruments are described below.

Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market prices comprise three types of risk: currency risk, interest rate risk and other price risk. Currency risk and interest rate risk are considered most relevant for the Group and are thus described below.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Group is primarily exposed to interest rate risk due to the interest-bearing loans and borrowings described in Note 19 which is used as the basis for the sensitivity analysis below.

The Group does not enter into derivatives to hedge interest rate risks.

The table below shows the effect on the Group's profit before tax if a reasonably possible change in the market interest rate had been applied to the risk exposure in existence at the end of the reporting period. No impact on equity is disclosed because the interest rates on the credit facilities are variable.

	2025	2024
	kEUR	kEUR
Change in interest rates		
Increase :		
+100 basis points	-1,100	-700
Decrease :		
-100 basis points	1,100	700

Since the amounts drawn from the revolving credit facility and the credit facility from Draupnir Holding B.V. (see further details in Note 19) have fluctuated significantly during 2025 and 2024, the Group does not believe that the year-end exposures reflect the exposures during the years. As a result, the sensitivity analysis above is considered unrepresentative for both years.

Currency risk

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. Currency risk arises on financial instruments that are denominated in a currency other than the functional currency in which they are measured.

The Group's exposure to currency risk is primarily related to two significant inter-company balances, an inter-company loan between PolyPeptide Laboratories Holding (PPL) AB (functional currency EUR) and PolyPeptide Laboratories Inc. (functional currency USD) and an inter-company receivable between the parent company, PolyPeptide Group AG (functional currency CHF), and PolyPeptide Laboratories Holding (PPL) AB denominated in Euro (EUR).

As of 1 October 2025, the inter-company loan between PolyPeptide Laboratories Holding (PPL) AB and PolyPeptide Laboratories Inc. was reclassified as part of the parent company's net investment in the subsidiary, as settlement is neither planned nor likely to occur in the foreseeable future. Accordingly, exchange differences arising from the translation of the loan are recognized in other comprehensive income and remain in equity, without subsequent reclassification to profit or loss, unless the net investment is disposed of.

As of 1 December 2024, the inter-company receivable between PolyPeptide Group AG, and PolyPeptide Laboratories Holding (PPL) AB was reclassified as part of the parent company's net investment in the subsidiary, as settlement of the receivable is neither planned nor likely to occur in the foreseeable future. As a result, the monetary item became, in substance, a part of the parent company's net investment in the subsidiary. As of 1 December 2024, exchange differences arising from the translation of the receivable into the functional currency of the parent company are thus initially recognized in other comprehensive income in the consolidated financial statements and reclassified to profit or loss on disposal of the net investment.

At the end of 2025, a reasonably possible change in the foreign exchange rate between CHF and EUR would thus have no impact on the Group's profit or loss and equity.

The Group is also exposed to currency risk from sales and purchases in currencies other than the functional currency of the operating sites. During 2025, the volume of such transactions increased to a level where management considers the exposure to be material in the context of the consolidated financial statements. In response, the Group has initiated an assessment of potential measures to mitigate this risk, including natural hedging strategies and the possible use of derivative instruments. The outcome of this assessment will guide future risk management practices.

In 2025 and 2024, the Group did not enter into derivatives to hedge currency risks.

Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. Concentrations of credit risk exist when changes in economic, industry or geographic factors similarly affect groups of counter-parties whose aggregate credit exposure is significant in relation to the Group's total credit exposure.

The Group has no significant credit risks, other than those that have already been allowed for, nor any concentrations of credit with a single customer or in an industry or geographical region that carries an unusually high credit risk.

Credit risks relating to the trade receivables and cash balances are monitored regularly. Clients are assessed according to Group criteria prior to entering into agreements. The maximum exposure to credit risk at the reporting date is the carrying value of each class of financial assets recognized in the consolidated statement of financial position.

Liquidity risk

Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset.

The Group monitors its liquidity risk by using a cash flow forecast model. This model considers the timing of expected cash inflows from payments from customers as well as expected cash outflows for inventories, investments, salaries, financial expenses, VAT, taxes, and other operating expenses. The Group uses the cash flow forecast model for reducing the amounts drawn from the credit facilities while still monitoring its liquidity risk.

The table below summarizes the maturity profile of the Group's financial liabilities as at 31 December based on contractual undiscounted payments.

KEUR	Less than 1 year	1-5 years	More than 5 years	Total
Year ended 2025				
Interest-bearing loans and borrowings	-544	-110,000	-	-110,544
Other financial liabilities	-1,395	-5,582	-6,977	-13,954
Lease liabilities	-5,081	-12,519	-4,988	-22,588
Trade payables	-66,808	-7,500	-	-74,308
Other current liabilities	-1,387	-	-	-1,387
Balance as at 31 December 2025	-75,215	-135,601	-11,965	-222,781

KEUR	Less than 1 year	1-5 years	More than 5 years	Total
Year ended 2024				
Interest-bearing loans and borrowings	-30,642	-40,000	-	-70,642
Other financial liabilities	-1,297	-5,190	-8,974	-15,461
Lease liabilities	-5,179	-13,454	-7,519	-26,152
Trade payables	-64,504	-11,250	-	-75,754
Other current liabilities	-2,850	-	-	-2,850
Balance as at 31 December 2024	-104,472	-69,894	-16,493	-190,859

Capital management

The primary objective of the Group's capital management is to safeguard the Group's ability to continue as a going concern while maintaining sound capital ratios in order to support its business and maximize shareholder value. The Group manages its capital structure and adjusts it in light of changes in economic conditions. To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. No changes were made to the objectives, policies or processes during the years ended 31 December 2025 and 31 December 2024.

The Group monitors capital using shareholder equity ratio, which is the total shareholder equity divided by total equity and liabilities, based on the consolidated financial statements. The Group has no formally approved ratio range but considers a ratio above 25% as being sound.

The table stated below shows the development of the shareholder equity ratio for the years 2025 and 2024.

KEUR	2025	2024
Total shareholder equity	340,598	357,244
Total equity and liabilities	825,959	756,576
Equity ratio as at 31 December	41.2%	47.2%

24 Financial instruments

Fair values

In view of their short-term nature, the fair values of financial instruments of cash, trade receivables and payables, and short-term liabilities approximate their carrying amounts. All financial assets and liabilities are measured at amortized cost except for the investment in a limited partnership (see Note 21), which is measured at fair value through profit or loss.

Set out below is a comparison by category of carrying amounts and fair values of all the Group's non-current financial instruments that are recognized in the consolidated statement of financial position.

kEUR	Carrying value		Fair value	
	2025	2024	2025	2024
Non-current financial assets				
Other financial assets	7,512	5,164	7,512	5,164
Non-current financial liabilities				
Interest-bearing loans and borrowings	109,034	39,420	110,000	40,000
Other financial liabilities	9,435	9,508	9,435	9,508

Fair value hierarchy

Quantitative disclosures of the Group's financial instruments in the fair value measurement hierarchy (see Note 1) are as follows:

kEUR	Level 1	Level 2	Level 3
As at 31 December 2025			
Other financial assets	–	–	7,512
Interest-bearing loans and borrowings	–	110,000	–
Other financial liabilities	–	9,435	–
As at 31 December 2024			
Other financial assets	–	–	5,164
Interest-bearing loans and borrowings	–	40,000	–
Other financial liabilities	–	9,508	–

The fair value of the financial assets and liabilities is included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. Level 1 inputs include the publicly listed share price of PolyPeptide Group AG. Level 2 inputs include the discounted cash flow method using a discount rate that reflects the issuer's borrowing rate as at the end of the reporting period. Level 3 inputs include unobservable inputs that reflect the assumptions that market participants would use when pricing the asset, including assumptions about risk.

25 Subsequent events

There have been no significant events subsequent to the balance sheet date that would require additional disclosure in the consolidated financial statements.

The consolidated financial statements for 2025 were approved for issue by the Board of Directors on 10 March 2026 and are subject to approval by the general meeting on 8 April 2026.



Phone +41 44 444 35 55
www.bdo.ch
zurich@bdo.ch

BDO Ltd
Schiffbaustrasse 2
8031 Zurich

STATUTORY AUDITOR'S REPORT

To the General Meeting of PolyPeptide Group AG, Baar

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the consolidated financial statements of PolyPeptide Group AG and its subsidiaries (the Group), which comprise the consolidated statement of financial position as at 31 December 2025, and the consolidated income statement, consolidated statement of comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including material accounting policy information.

In our opinion the consolidated financial statements (pages 169 to 216) give a true and fair view of the consolidated financial position of the Group as at 31 December 2025 and its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with IFRS Accounting Standards and comply with Swiss law.

Basis for Opinion

We conducted our audit in accordance with Swiss law, International Standards on Auditing (ISAs) and Swiss Standards on Auditing (SA-CH). Our responsibilities under those provisions and standards are further described in the "Responsibilities of the Auditor for the Audit of the Consolidated Financial Statements" section of our report. We are independent of the Group in accordance with the provisions of Swiss law, together with the requirements of the Swiss audit profession that are relevant to audits of the financial statements of public interest entities, as well as those of the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (*including International Independence Standards*) (IESBA Code), as applicable to audits of financial statements of public interest entities. We have also fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

BDO Ltd, a limited company under Swiss law, incorporated in Zurich, forms part of the international BDO Network of independent member firms.



Phone +41 44 444 35 55
www.bdo.ch
zurich@bdo.ch

BDO Ltd
Schiffbaustrasse 2
8031 Zurich

Key Audit Matter	How the Key Audit Matter was addressed in the audit
------------------	---

<p>Revenue recognition</p> <p>The Group has recognised revenue of kEUR 389,327 (2024: kEUR 336,792). The Group earns the majority of its revenues from the sale of goods (Active Pharmaceutical Ingredients), which are recognised at a point in time and a portion of its revenues in connection with pharmaceutical services with revenue recognised typically on an over time basis.</p> <p>Due to the significant expected growth of revenues from Active Pharmaceutical Ingredients (API), the fact that sales contracts include many different terms, there is a risk of incorrect timing of revenue recognition due to fraud or error, the significant level of judgement and estimate involved by management in assessing revenue recognition over time related to pharmaceutical services, where contracts run longer than a year and the linkage of certain management incentive compensation to revenue targets, we consider revenue to be a key audit matter.</p> <p>We refer to Note 1 Summary of material accounting policy information and Note 3 Revenue and expenses.</p>	<p>We obtained an understanding of the control environment and performed a walkthrough of the revenue and receipts cycle as part of the risk assessment process.</p> <p>We performed tests of transactions for revenues, specific procedures on sales orders opened during the financial year 2025 but not closed as of 31 December 2025, credit memo testing, cut-off procedures by reviewing the shipping logs shortly before and after year-end and testing samples before and after the year-end.</p> <p>We have obtained the invoice journal and verified it to the general ledger. We have reconciled the sales prices and quantities to contracts and delivery notes on a sample basis. We have verified credit entries posted within trade receivables and related to bank receipts only. We have verified that all goods that have been shipped from the site are also invoiced at the balance sheet date or recorded as accrued income.</p> <p>We tested appropriate timing of revenue recognition by comparing individual sales transactions to delivery documents and effective execution of performance obligations. We analyzed revenue transactions using computer aided audit and data analysis techniques. We reviewed the calculation of percentage of completion and the related revenue and margin recognised for a selection of projects. We requested confirmation of revenues from significant customers through a confirmation directly from the third party.</p> <p>Furthermore, we have assessed the adequacy of the disclosures relating to revenue recognition in the notes.</p>
---	--

Other Information

The board of directors is responsible for the other information. The other information comprises the information included in the annual report, but does not include the consolidated financial statements, the financial statements, the compensation report and our auditor's reports thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

BDO Ltd, a limited company under Swiss law, incorporated in Zurich, forms part of the international BDO Network of independent member firms.



Phone +41 44 444 35 55
www.bdo.ch
zurich@bdo.ch

BDO Ltd
Schiffbaustrasse 2
8031 Zurich

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements, or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Board of Directors for the Consolidated Financial Statements

The board of directors is responsible for the preparation of the consolidated financial statements that give a true and fair view in accordance with IFRS Accounting Standards and the provisions of Swiss law, and for such internal control as the board of directors determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the board of directors is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the board of directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Responsibilities of the Auditor for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Swiss law, ISAs and SA-CH will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

A further description of the auditor's responsibilities for the audit of the consolidated financial statements is located at EXPERTsuisse's website at: <https://www.expertsuisse.ch/en/audit-report-for-ordinary-audits>. This description forms part of our auditor's report.

Report on Other Legal and Regulatory Requirements

In accordance with Art. 728a para. 1 item 3 CO and PS-CH 890, we confirm that an internal control system exists, which has been designed for the preparation of consolidated financial statements according to the instructions of the board of directors.

We recommend that the consolidated financial statements submitted to you be approved.

Zurich, 10 March 2026

BDO Ltd

René Füglistner
Licensed Audit Expert
Auditor in Charge

Jan Trautwein
Licensed Audit Expert

BDO Ltd, a limited company under Swiss law, incorporated in Zurich, forms part of the international BDO Network of independent member firms.

Financial Report

Financial statements of PolyPeptide Group AG

221 Income statement of PolyPeptide Group AG

222 Statement of financial position of PolyPeptide Group AG

224 Notes to the financial statements of PolyPeptide Group AG

231 Proposal for the appropriation of accumulated deficit

232 Report on the Audit of the Financial Statements of PolyPeptide Group AG

Income statement of PolyPeptide Group AG

1 January–31 December

kCHF	Note	2025	2024
Financial income	7	9,790	16,720
Service income		-395	9,603
Total income		9,395	26,323
Personnel expenses		-9,204	-5,767
Other operating expenses		-3,182	-2,284
Interest expenses third parties		-3,468	-3,003
Interest expenses related parties		-1,240	-2,804
Other financial expenses	8	-3,033	-2,689
Depreciation on tangible assets		-96	-404
Impairment loss/reversal on investments	9	-695,962	326,400
Operating result before taxes (EBT)		-706,790	335,772
Taxes		-	-
Net loss/profit for the year		-706,790	335,772

Statement of financial position of PolyPeptide Group AG

As at 31 December

Assets, kCHF	Note	2025	2024
Current assets			
Cash and cash equivalents	1	400	224
Loan to group companies		90,972	65,459
Other receivables from third parties		330	–
Other receivables from group companies		41,396	40,479
Accrued income and prepaid expenses		724	691
Total current assets		133,822	106,853
Non-current assets			
Loan to group companies		125,254	126,575
Financial assets	3	7,525	5,221
Investments	2	155,738	851,700
Tangible assets		490	586
Total non-current assets		289,007	984,082
Total assets		422,829	1,090,935

Statement of financial position of PolyPeptide Group AG (continued)

As at 31 December

Liabilities, kCHF	Note	2025	2024
Current liabilities			
Other liabilities due to third parties		967	1,354
Interest-bearing liabilities due to shareholder		293	28,730
Accrued expenses and deferred income		2,465	36
Total short-term liabilities		3,725	30,120
Non-current liabilities			
Interest-bearing liabilities due to third parties		83,822	37,647
Interest-bearing liabilities due to shareholder		18,627	–
Total long-term liabilities		102,449	37,647
Shareholders' equity			
Share capital	4	331	331
Statutory capital reserves			
Reserves from capital contribution	5	2,104,803	2,104,803
Other capital reserves		4,949	4,949
Treasury shares	6	-7,232	-9,043
Net loss brought forward		-1,077,872	-1,412,542
Net loss on sale of treasury shares		-1,534	-1,102
Net loss/profit for the year		-706,790	335,772
Total shareholders' equity		316,655	1,023,168
Total liabilities and shareholders' equity		422,829	1,090,935

Notes to the financial statements of PolyPeptide Group AG

General information

Accounting policies

These financial statements were prepared in accordance with the provisions of the Swiss Law on Accounting and Finance Reporting (32nd title of the Swiss Code of Obligations). Significant valuation principles that have been applied in the preparation of these financial statements that are not prescribed by law are described below.

Presentation of cash flow statement and additional disclosures in the notes dispensed with

As PolyPeptide Group AG, Baar (the "Company") has prepared consolidated financial statements under a recognized accounting standard (IFRS), it has decided, in accordance with the law, to dispense with the presentation of information on interest-bearing liabilities and audit fees in the notes, a cash flow statement, and an annual review.

Financial year

The financial year runs from 1 January to 31 December.

Valuation principles

Assets are valued at no more than cost. Liabilities are carried at nominal value.

All assets and liabilities in foreign currencies are translated by applying the exchange rate prevailing on the balance sheet date. Exchange differences are recognized in the income statement.

Earnings and expenses originated in foreign currencies are translated with the monthly exchange rate.

Investments

Investments are shown at individual historical acquisition costs less impairment, if any.

Own shares

Own shares are recognized in equity as a negative item at cost as per the date of acquisition. In the event of a subsequent sale, a gain is recognized in other capital reserves and a loss is recognized in the accumulated deficit.

Share-based payments

Part of the variable compensation paid to members of the Executive Committee, selected key employees and part of the compensation paid to members of the Board of Directors is in the form of Company shares. The acquisition cost of the shares is recorded under personnel expenses.

Declaration of the number of full-time equivalents (FTEs)

The average number of full-time positions during the reporting was below 50.

1 Cash and cash equivalents

kCHF	2025	2024
Cash	400	224
Balance as at 31 December	400	224

2 Investments

There were no changes to the investments held by the Company during 2025. As a result, the table below shows the direct and significant indirect investments held by the Company as at 31 December 2025 and as at 31 December 2024:

Group companies	Location	Capital and voting shares	
		Direct	Indirect
Polypeptide Laboratories Holding (PPL) AB	Limhamn, Sweden	100%	
Polypeptide Laboratories (Sweden) AB	Limhamn, Sweden		100%
PolyPeptide SA	Braine-l'Alleud, Belgium		100%
PolyPeptide Laboratories France S.A.S.	Strasbourg, France		100%
PolyPeptide Laboratories Inc.	Torrance, CA, USA		100%
PolyPeptide Laboratories San Diego, LLC ¹	San Diego, CA, USA		100%
PolyPeptide Laboratories Pvt. Ltd.	Ambarnath (East), India		100%
PolyPeptide Laboratories A/S ²	Hillerød, Denmark		100%

¹ PolyPeptide Laboratories San Diego, LLC is a wholly owned subsidiary of PolyPeptide Laboratories Inc.

² PolyPeptide Laboratories A/S is a dormant company.

Percentage of voting shares is equal to percentage of ownership.

3 Contingent liabilities and guarantees

Limited Partnership Investments

	2025		2024	
	kUSD	kCHF	kUSD	kCHF
Uncalled capital commitment as at 31 December	17,400	13,793	21,000	19,025

Limited partnership investments

In November 2021, the Company entered into a limited partnership agreement. The Company committed to invest a maximum amount of kUSD 30,000.

A capital call was made during 2025, where the Company invested kUSD 3,600 in addition to investments made in prior years. As a result, an uncalled capital commitment of kUSD 17,400 as at 31 December 2025 is disclosed in the table above.

If the general partner of the limited partnership makes an additional capital call, the Group would be obliged to pay the amount within ten business days.

Guarantee pension fund

All members of the PRI Pensionsgaranti, the issuer of the defined benefit plan in Sweden, are subject to a mutual liability. This liability would only be invoked in the event that PRI Pensionsgaranti has consumed all its assets. The mutual liability of the Group is limited to a maximum of 2% of the Group's individual pension liability with PRI Pensionsgaranti. As such, the Group has a contingent liability of kEUR 325 as at 31 December 2025 (2024: kEUR 288), for which it has issued a guarantee to PRI Pensionsgaranti.

Parent guarantee

The Company has provided three guarantees in favor of two of the Company's fully directly and indirectly owned subsidiaries. As of 31 December 2025, the guaranteed amount was mEUR 144 (2024: mEUR 102).

4 Share capital

There have been no changes to the share capital of PolyPeptide Group AG during 2025. As a result, the share capital of PolyPeptide Group AG comprised 33,125,001 registered shares with a nominal value of CHF 0.01 each as at 31 December 2025.

5 Reserves from capital contributions

CHF	2025	2024
Reserves from capital contributions (foreign)	1,909,783,753	1,909,783,753
Reserves from capital contributions (domestic)	195,019,440	195,019,440
Total reserves from capital contribution as at 31 December	2,104,803,193	2,104,803,193

The reported reserves from capital contributions as capital contributions within the meaning of Art. 5 para. 1 bis (for the part of the "domestic KER") or Art. 5 para. 1 quater lit. a of the Withholding Tax Act (for the part of the "foreign KER") have been confirmed by the Swiss Federal Tax Administration as at 30 January 2024.

6 Treasury shares

2025	No. of shares	Average prices in CHF
Own shares as at 1 January 2025	128,505	70.38
Purchase	25,455	18.14
Transfer to Board members / executive committee (incl. group companies)	-35,524	64.00
Own shares as at 31 December 2025	118,436	61.06

2024	No. of shares	Average prices in CHF
Own shares as at 1 January 2024	155,494	70.38
Purchase	–	–
Transfer to Board members / executive committee (incl. group companies)	-26,989	70.38
Own shares as at 31 December 2024	128,505	70.38

From April to May 2025, PolyPeptide Group AG purchased 25,455 own shares at the average price of CHF 18.14 to be held as treasury shares (2024: nil). During 2025, 35,524 shares were transferred to Board members as part of their share-based remuneration (2024: 26,989 shares transferred to Board members as part of their share-based remuneration).

7 Financial income

kCHF	2025	2024
Interest income from group companies	9,790	14,113
Foreign exchange result	–	2,607
Total financial income	9,790	16,720

8 Other financial expenses

kCHF	2025	2024
Foreign exchange result	-2,333	–
Other financial expenses	-699	-2,689
Total other financial expenses	-3,033	-2,689

9 Impairment loss/reversal on investments

In 2025, PolyPeptide Group AG reassessed the valuation approach for its investment in PolyPeptide Laboratories Holding (PPL) AB in accordance with the Swiss Code of Obligations. Management determined that the quoted market price of PolyPeptide Group AG no longer provided the most appropriate basis for estimating the recoverable amount of the investment.

The recoverable amount is now determined with reference to the consolidated IFRS net-equity value of PolyPeptide Laboratories Holding (PPL) AB and its subsidiaries, which is considered a more reliable indicator under the current circumstances. Based on this updated methodology, the impairment test resulted in an impairment loss of kCHF 695,962 reducing the carrying amount to its recoverable value at year-end.

In prior years, the valuation had been based on the market price of PolyPeptide Group AG shares, which had resulted in a cumulative impairment loss of kCHF 1,068,000 in the years 2021 to 2024.

10 Share ownership of the Board of Directors and the Executive Committee

As at 31 December 2025:

	Function	Number of shares	which are blocked	allocated in the reporting period
Klaus Peter Wilden	Chair	42,179	33,777	11,489
Patrick Aebischer	Vice-Chair, Lead Independent Director	27,666	22,348	7,660
Jane Anne Salik	Independent Member	29,184	9,631	3,302
Erik Schropp	Member	3,193	–	–
Philippe Weber	Independent Member	30,556	24,721	8,485
Jo LeCouilliard ¹⁾	Independent Member	2,933	2,933	2,933
Beat In-Albon ²⁾	Independent Member	n/a	n/a	1,655
Total Board of Directors		135,711	93,410	35,524

	Function	Number of shares	which are blocked	allocated in the reporting period
Juan Jose Gonzalez	CEO	227,842	–	–
Marc Augustin	CFO	2,500	–	–
Christina Del Vecchio	Chief Legal Officer	–	–	–
Raoul Bernhardt ³⁾	Chief Manufacturing and Supply Chain Officer	–	–	–
Jens Fricke ⁴⁾	Director Global Operations	n/a	–	–
Total Executive Committee		230,342	–	–

Total		366,053	93,410	35,524
--------------	--	----------------	---------------	---------------

¹ Member of the Board as of 9 April 2025

² Member of the Board until 9 April 2025

³ Member of the Executive Committee since 11 August 2025

⁴ Member of the Executive Committee until 10 August 2025

As at 31 December 2024:

	Function	Number of shares	which are blocked	allocated in the reporting period
Klaus Peter Wilden	Chair	30,690	29,032	8,254
Patrick Aebischer	Vice-Chair	20,006	18,901	5,503
Beat In-Albon	Member	17,196	16,201	4,142
Jane Anne Salik	Member	25,882	8,145	2,371
Erik Schropp	Member	3,193	–	–
Philippe Weber	Member	22,071	20,846	6,095
Dorothee Deuring ¹⁾	Member	3,624	3,624	624
Total Board of Directors		122,662	96,749	26,989

	Function	Number of shares	which are blocked	allocated in the reporting period
Juan Jose Gonzalez	CEO	227,842	–	–
Marc Augustin ²⁾	CFO	2,500	–	–
Christina Del Vecchio	General Counsel	–	–	–
Neil James Thompson ³⁾	Director Global Sales and Marketing	1,122	–	–
Jens Fricke	Director Global Operations	1,380	–	–
Total Executive Committee		232,844	–	–
Total		355,506	96,749	26,989

¹⁾ Member of the Board until 10 April 2024.

²⁾ Member of the Executive Committee as of 1 January 2024.

³⁾ Stepped down as Director Global Sales and Marketing and member of the Executive Committee as of 26 April 2024.

11 Residual amount of leasing obligations

The maturity of leasing obligations which have a residual term of more than twelve months or which cannot be canceled within the next twelve months is as follows:

kCHF	31 December 2025	31 December 2024
0-1 years	118	118
1-5 years	470	472
More than 5 years	147	265
Total	735	855

12 Subsequent events

There have been no significant events subsequent to the balance sheet date that would require additional disclosure in the financial statements.

The financial statements for 2025 were approved for issue by the Board of Directors on 10 March 2026 and are subject to approval by the general meeting on 8 April 2026.

Proposal for the appropriation of accumulated deficit

The Board of Directors proposes that the general meeting approves that the accumulated deficit of CHF 1,786,196,497 be carried forward to the new account.

Appropriation of accumulated deficit

CHF	2025
Net loss brought forward	-1,077,871,571
Net loss on sale of treasury shares	-1,534,319
Net loss for the year	-706,790,607
Accumulated deficit to be carried forward	-1,786,196,497



Phone +41 44 444 35 55
www.bdo.ch
zurich@bdo.ch

BDO Ltd
Schiffbaustrasse 2
8031 Zurich

STATUTORY AUDITOR'S REPORT

To the General Meeting of PolyPeptide Group AG, Baar

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of PolyPeptide Group AG (the Company) - which comprise the balance sheet as at 31 December 2025, and the income statement for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion the financial statements (pages 221 to 231) comply with Swiss law and the articles of incorporation.

Basis for Opinion

We conducted our audit in accordance with Swiss law and Swiss Standards on Auditing (SA-CH). Our responsibilities under those provisions and standards are further described in the "Responsibilities of the Auditor for the Audit of the Financial Statements" section of our report. We are independent of the Company in accordance with the provisions of Swiss law, together with the requirements of the Swiss audit profession, applicable to financial audits of public interest entities. We have also fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

BDO Ltd, a limited company under Swiss law, incorporated in Zurich, forms part of the international BDO Network of independent member firms.



Phone +41 44 444 35 55
www.bdo.ch
zurich@bdo.ch

BDO Ltd
Schiffbaustrasse 2
8031 Zurich

Key Audit Matter	How the Key Audit Matter was addressed in the audit
------------------	---

<p>Investments</p> <p>As of 31 December 2025, the book value of investments amounted to kCHF 155,738 (31 December 2024: kCHF 851,700) in PolyPeptide Laboratories Holding (PPL) AB, Sweden. Investments are carried at historical acquisition costs less impairment charges.</p> <p>We consider the valuation of investments in PolyPeptide Laboratories Holding (PPL) AB, Sweden to be a key audit matter owing to the magnitude of the balance in relation to the financial statements and the reassessment of the recoverable amount.</p> <p>There is a significant risk that carrying investments are not recoverable. We refer to Note General Information - Investments, Note 2 Investments and Note 9 Impairment loss/reversal on investments.</p>	<p>We performed the following audit procedures:</p> <p>We obtained and reviewed management's memorandum addressing the impairment loss as well as the reassessment of the recoverable amount in PolyPeptide Laboratories Holding (PPL) AB, Sweden.</p> <p>We reviewed presentation and disclosure of the impairment loss in PolyPeptide Laboratories Holding (PPL) AB, Sweden and recalculated the impairment loss recognised.</p> <p>We reconciled the carrying amount of the investment to the consolidated IFRS net-equity value of PolyPeptide Laboratories Holding (PPL) AB and its subsidiaries.</p> <p>Moreover, we have assessed the adequacy of the disclosures relating to the impairment loss and the reassessment of the recoverable amount in the notes.</p>
--	---

Other Information

The board of directors is responsible for the other information. The other information comprises the information included in the annual report, but does not include the financial statements, the consolidated financial statements, the compensation report and our auditor's reports thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Board of Directors for the Financial Statements

The board of directors is responsible for the preparation of the financial statements in accordance with the provisions of Swiss law and the article of incorporation, and for such internal control as the board of directors determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the board of directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the board of directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

BDO Ltd, a limited company under Swiss law, incorporated in Zurich, forms part of the international BDO Network of independent member firms.



Phone +41 44 444 35 55
www.bdo.ch
zurich@bdo.ch

BDO Ltd
Schiffbaustrasse 2
8031 Zurich

Responsibilities of the Auditor for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Swiss law and SA-CH will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of the auditor's responsibilities for the audit of the financial statements is located at EXPERTsuisse's website at: <https://www.expertsuisse.ch/en/audit-report-for-ordinary-audits>. This description forms part of our auditor's report.

Report on Other Legal and Regulatory Requirements

In accordance with Art. 728a para. 1 item 3 CO and PS-CH 890, we confirm that an internal control system exists, which has been designed for the preparation of financial statements according to the instructions of the board of directors.

Based on our audit in accordance with Art. 728a para. 1 item 2 CO, we confirm that the proposal of the board of directors complies with Swiss law and the Company's articles of incorporation. We recommend that the financial statements submitted to you be approved.

Zurich, 10 March 2026

BDO Ltd

René Füglistner
Licensed Audit Expert
Auditor in Charge

Jan Trautwein
Licensed Audit Expert

BDO Ltd, a limited company under Swiss law, incorporated in Zurich, forms part of the international BDO Network of independent member firms.

Three-year financial history¹

kEUR	2025	2024	2023
Income and expenses			
Revenue	389,327	336,792	320,372
Total income	391,949	338,770	324,853
Cost of sales	-325,336	-299,422	-315,730
Total operating expenses	-57,924	-46,712	-45,591
o/w Depreciation, amortization and impairment	-38,066	-32,714	-30,469
Financial income	1,843	6,802	103
Financial expenses	-30,589	-17,583	-21,878
Income tax	-1,112	-1,419	6,803
Result for the year	-21,169	-19,564	-51,440
Performance			
Gross profit	66,613	39,348	9,123
Gross margin in % of revenue	17.1%	11.7%	2.8%
EBITDA	46,755	25,350	-5,999
EBITDA in % of revenue	12.0%	7.5%	-1.9%
Operating result (EBIT)	8,689	-7,364	-36,468
Operating result (EBIT) in % of revenue	2.2%	-2.2%	-11.4%
Earnings per share (EUR), basic	-0.64	-0.59	-1.56
Return on net operating assets (RONOA)	1.6%	-1.6%	-8.5%
Financial position			
Total assets	825,959	756,576	689,088
Non-current assets	501,083	428,354	362,486
Current assets	324,876	328,222	326,602
Total equity and liabilities	825,959	756,576	689,088
Equity	340,598	357,244	381,225
Non-current liabilities	298,828	204,829	131,413
Current liabilities	186,533	194,503	176,450
Cash flows			
Net cash flows from operating activities	77,510	89,399	36,485
Net cash flows from investing activities	-111,710	-91,018	-59,512
Net cash flows from financing activities	33,792	-25,323	84,547
Cash and cash equivalents at the end of the year	74,589	68,277	95,706
Employees			
Employees (# of FTEs, average)	1,395	1,291	1,202

¹ This table includes references to alternative financial performance measures (APM) that are not defined or specified by IFRS. These APM should be regarded as complementary information to and not as substitutes of the Group's consolidated financial results based on IFRS. For the definitions of the main operational indicators and APM used, including related abbreviations, as well as for selected reconciliations to IFRS, please refer to the section "Definitions and reconciliations" of this report.

Definitions and Reconciliations

Selected information provided in this report includes operational indicators or Alternative Financial Performance Measures (APM) that are not accounting measures defined by IFRS. The Group believes that investor understanding of PolyPeptide's performance is enhanced by disclosing such indicators and measures, since they provide additional insights into the underlying business, strategic progress and/or financial performance. Operational indicators and APMs should not be considered as substitutes to the Group's consolidated financial results based on IFRS. They may not be comparable to similarly titled measures by other companies. This section includes the definitions of the main operational indicators and APMs provided as well as a reconciliation of selected APMs to the most directly reconcilable IFRS line item.

237 Abbreviations

238 Operational indicators

239 Alternative financial performance measures (APM)

240 Reconciliations

242 Legal note

243 Imprint

Abbreviations

API – Active Pharmaceutical Ingredient	ICH – International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use
APM – Alternative Financial Performance Measure	ILO – International Labor Organization
CAGR – Compound Annual Growth Rate	ISO – International Organization for Standardization
CDMO – Contract Development and Manufacturing Organization	IPO – Initial Public Offering
CDP – Carbon Disclosure Project	LCM – Life Cycle Management
cGMP – current Good Manufacturing Practice	LTI – Lost Time Injuries
CO – Code of Obligation	NDA – New Drug Application
CMC – Chemistry, Manufacturing & Controls	OECD – Organization for Economic Cooperation and Development
CO ₂ (e) – Carbon dioxide (equivalent)	PPQ – Process Performance Qualification
CSRD – Corporate Sustainability Reporting Directive	R&D – Research & Development
DDTrO – Ordinance on Due Diligence and Transparency in relation to Minerals and Metals from Conflict-Affected Areas and Child Labor	SBTi – Science Based Targets initiative
DMF – Dimethylformamide	SDG – Sustainable Development Goals
DP – Drug Product	SIX – SIX Swiss Exchange
DS – Drug Substance	SOC – Substance of concern
EHS – Employee Health & Safety	SVHC – Substance of very high concern
ESG – Environmental, Social and Governance	SPPS – Solid Phase Peptide Synthesis
ESRS – European Sustainability Reporting Standards	TCFD – Task Force on Climate-related Financial Disclosure
FTE – Full-time equivalent	UN – United Nations
GHG – Greenhouse Gas Protocol	UNICEF – United Nations Children’s Fund
GRI – Global Reporting Initiative	

Operational indicators

As part of our financial disclosure, we report revenue from our custom development projects business area, and we occasionally make implicit or explicit reference to the underlying project pipeline as an indicator to measure operational performance. This includes the number of projects in clinical development in total or in categories. Our project count for a given period has been measured based on the initiation of a project, e.g. formal signatures or acceptance of a purchase order. Projects with parallel activities at more than one site, or which are transferred from one site to another, or which included multiple peptides are counted as one project. The synthesis or one-time manufacturing of small quantities of peptides, mostly for research or academic use, is not considered as a project.

Our reference to

- **pre-clinical projects** includes non-GMP manufacturing for the lead candidate selection, and subsequent non-GMP manufacture of the selected API for pre-clinical and toxicological studies;
- **phase I, phase II and phase III projects** includes GMP manufacturing of the API for phase I, phase II and phase III clinical trials, including analytical method validation, stability studies, process and analytical development as well as regulatory documentation.

Active custom projects include (i) projects with ongoing manufacturing activities; (ii) projects with ongoing non-manufacturing activities (development, analytical services, regulatory, stability studies); (iii) projects with open orders in the Group's accounting system pending to be delivered; and (iv) projects that are active on the customer's end, but not necessarily active at PolyPeptide (i.e., when the customer is conducting pre-clinical or clinical studies, formulation studies, etc.).

Reference to "peptides" is to a chemical entity (CE) with a unique amino acid sequence regardless of production site or manufacturing process. A "pipeline peptide" is a new chemical entity (NCE) in pre-clinical or clinical phase of development and a "commercial peptide" is a NCE commercially approved on the market.

A "commercial project" relates to the manufacturing of commercial peptide. This includes therapeutic API or intermediates with regulatory approval, both for the innovator or for a generic drug manufacturer. A commercial project may also include material for diagnostic, cosmetic or veterinary purposes.

References to "Development revenue" and "Commercial revenue" are based on the business area definitions set out in [note 3 "Revenue and expenses" of the consolidated financial statements in the Financial Report 2025](#).

Alternative Financial Performance Measures (APM)

Revenue at constant currency rate: Revenue translated into the presentation currency, EUR, using the weighted average EUR currency exchange rate from the prior period. This measure provides additional transparency on revenue trends by excluding the impact of fluctuations in exchange rates.

Gross Margin: Gross profit as a percentage of revenue.

EBITDA: Operating result (EBIT) plus depreciation, amortization and impairment charges (if any).

EBITDA Margin: EBITDA as a percentage of revenue.

Operating result (EBIT): Earnings before total financial result and income tax charge.

Capital expenditures (Capex): Investments in property, plant and equipment assets and intangible assets capitalized during a reporting period.

Net operating assets: The sum of Non-current assets plus Current assets less Cash and cash equivalents less Current liabilities.

Return on net operating assets (RONOA): Last twelve months Operating result in percentage of average Net operating assets.

Equity ratio: Equity at the end of the period divided by Total assets at the end of the period.

Free Cash Flow (FCF): Net cash flows from operating activities less cash paid for acquisition of intangible assets less cash paid for acquisition of property, plant and equipment assets.

Net Cash: Cash and cash equivalents less lease liabilities less other financial liabilities.

Headcount: Number of people employed by PolyPeptide at the time indicated (i.e., excluding contractors).

Reconciliations

Revenue at constant currencies¹

kEUR	2025	2024
Revenue at constant currency rates ¹	390,628	336,653
Impact from changes in exchange rates compared to prior period	-1,301	139
Revenue reported (IFRS)	389,327	336,792

¹ Revenue translated into the presentation currency, EUR, using the weighted average EUR currency exchange rate from the prior period.

Change in revenue

	2025 vs 2024	2024 vs 2023
Change in revenue reported (IFRS) (%)	15.6%	5.1%
Change in revenue at constant currency rates (%) ¹	16.0%	5.1%

¹ The change is calculated as: (Current period's revenue at constant currencies) / (Prior period's revenue reported (IFRS)) - 1.

Revenue by business area, excl. coronavirus pandemic (2025 vs 2024 and 2021)

kEUR	2025	2024	2021
Commercial revenue	235,896	218,644	115,120
Development revenue, excl. revenue associated with the coronavirus pandemic	153,431	118,148	103,812
Revenue associated with the coronavirus pandemic	–	–	63,194
Revenue reported (IFRS)	389,327	336,792	282,126

Revenue by therapeutic area, excl. coronavirus pandemic (2025 vs 2024 and 2021)

kEUR	2025	2024	2021
Metabolic	220,573	133,363	62,219
Oncologic	39,359	56,245	40,189
Other, excl. revenue associated with the coronavirus pandemic	129,395	147,184	116,524
Revenue associated with the coronavirus pandemic	–	–	63,194
Revenue reported (IFRS)	389,327	336,792	282,126

Revenue by customer type, excl. coronavirus pandemic (2025 vs 2024 and 2021)

kEUR	2025	2024	2021
Large pharma	243,768	205,504	119,429
Biotech, excl. revenue associated with the coronavirus pandemic	87,498	91,968	66,710
Other	58,061	39,320	32,793
Revenue associated with the coronavirus pandemic	–	–	63,194
Revenue reported (IFRS)	389,327	336,792	282,126

Operating result to EBITDA

kEUR	2025	2024
Operating result (EBIT)	8,689	-7,364
Depreciation, amortization and impairment charges (if any)	38,066	32,714
EBITDA	46,755	25,350

Return on net operating assets (RONOA)¹

kEUR	2025	2024
Operating result (EBIT)	8,689	-7,364
Average ¹ Net operating assets:		
Total non-current assets (average)	464,719	395,420
Total current assets (average)	326,549	327,412
Cash and cash equivalents (average)	-71,433	-81,992
Total current liabilities (average)	-190,518	-185,477
Average ¹ Net operating assets	529,317	455,363
Return on net operating assets (RONOA)	1.6%	-1.6%

¹ The average amounts are calculated as: (Current period's figures + prior period's figures) / 2.

Free Cash Flow

kEUR	2025	2024
Net cash flows from operating activities	77,510	89,399
Acquisition of intangible assets	-1,152	-1,217
Acquisition of property, plant and equipment	-107,753	-85,751
Free Cash Flow	-31,395	2,431

Net Cash

kEUR	2025	2024
Cash and cash equivalents	74,589	68,277
Interest-bearing liabilities (Total financial debt):		
Interest-bearing loans and borrowings (Non-current)	-109,034	-39,420
Lease liabilities (Non-current)	-15,979	-18,982
Other financial liabilities (Non-current)	-9,435	-9,508
Interest-bearing loans and borrowings (Current)	-544	-30,642
Lease liabilities (Current)	-5,008	-5,073
Other financial liabilities (Current)	-1,361	-1,266
Interest-bearing liabilities (Total financial debt)	-141,361	-104,891
Net Cash / (debt)	-66,772	-36,614

Capital expenditures (Capex)

kEUR	2025	2024
Property, plant and equipment assets capitalized	108,806	86,777
Intangible assets capitalized	1,172	1,062
Capital expenditures (Capex)	109,978	87,839

Legal Note

Cautionary statement on forward-looking information: This report has been prepared by PolyPeptide Group AG and includes forward-looking information and statements concerning the outlook for the Group's business. These statements are based on current expectations, estimates and projections about the factors that may affect the Group's future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as "expects", "believes", "estimates", "targets", "plans", "projects", "outlook" or similar expressions.

There are numerous risks, uncertainties and other factors, many of which are beyond PolyPeptide Group AG's control, that could cause the Group's actual results to differ materially from the forward-looking information and statements made in this Annual Report and that could affect the Group's ability to achieve its stated targets. The important factors that could cause such differences include, among others: timing and strength of its customer's product offerings, relationships with employees, customers and other business partners; strategies and initiatives of competitors; manufacturing capacity and utilization; quality issues; supply chain matters; the ability to continue to obtain sufficient financing to meet growth initiatives and liquidity needs; legal, tax or regulatory disputes; and changes in the political, social and regulatory framework in which the Group operates, or in economic or technological trends or conditions, including currency fluctuations, inflation and consumer confidence, on a global, regional or national basis. Although PolyPeptide Group AG believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved.

In particular, the statements in the sections on mid-term outlook and guidance for 2026 constitute forward-looking statements and are not guarantees of future financial performance. PolyPeptide Group AG's actual results of operations could deviate materially from those set forth in these sections as a result of the factors described above or other factors. As such, investors should not place undue reliance on the statements in the sections on mid-term outlook and guidance for 2026.

Except as otherwise required by law, PolyPeptide Group AG disclaims any intention or obligation to update any forward-looking statements as a result of developments.

Alternative Financial Performance Measures (APM): This report contains references to operational indicators, such as active custom projects and commercial projects, and APM that are not defined or specified by IFRS, including revenue at constant currency rates, EBITDA, EBITDA margin, net operating assets, return on net operating assets (RONOA), capital expenditures (Capex), free cash flow, net cash, and headcount. These APM should be regarded as complementary information to and not as substitutes for the Group's consolidated financial results based on IFRS. These APM may not be comparable to similarly titled measures disclosed by other companies. For the definitions of the main operational indicators and APM used, including related abbreviations, as well as for selected reconciliations to IFRS, refer to the section "Definitions and reconciliations" in this report.

For the purposes of this report, unless the context otherwise requires, the term "the Company" means PolyPeptide Group AG, and the terms "PolyPeptide", "the Group", "we", "us" and "our" mean PolyPeptide Group AG and its consolidated subsidiaries. In various tables, the use of "-" indicates not meaningful or not applicable. Some non-financial figures in the Sustainability Report 2025 have been rounded. Percentages may have been calculated using rounded numbers.

The PolyPeptide Annual Report 2025 PDF version legally prevails over the PolyPeptide Annual Report 2025 online version.

Imprint

Contact

PolyPeptide Group AG
Neuhofstrasse 24
6340 Baar, Switzerland
[polypeptide.com](https://www.polypeptide.com)

Investor Relations
Phone: +41 (0) 43 502 05 80
investorrelations@polypeptide.com
<https://www.polypeptide.com/investors/>

Media / Corporate Communications
Phone: +41 (0) 43 502 05 80
mediateam@polypeptide.com
<https://www.polypeptide.com/news/>

Corporate Responsibility
Phone: +41 (0) 43 502 05 80
sustainability@polypeptide.com

Share register and share information

areg.ch
Fabrikstrasse 10
4614 Hägendorf, Switzerland
Phone: +41 (0) 62 209 16 60
info@areg.ch

Share information
Listing: SIX Swiss Exchange (International Reporting Standard)
Ticker: PPGN
Valor number: 111076085
ISIN: CH1110760852

Publisher's note

Corporate Communications: PolyPeptide Group AG, Baar
Concept, layout and realization: NeidhartSchön, Zurich
Publishing system: ns.wow by Multimedia Solutions AG, Zurich
Consultant on materiality and ESRS reporting: Sustainerv GmbH, Zurich

Pictures and illustrations: PolyPeptide Group, Baar, Markus Forte, Zurich, Patrick Gutenberg, Zurich, Bernard Babette, Brussel South

Publication date Annual Report 2025: 12 March 2026.

